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NEW INSIGHTS INTO MOLECULAR MECHANISM OF 
FLUDARABINE 
ALINA D. BULGAR 
ABSTRACT 
 
 Nucleotide analogs (e.g. fludarabine) are antimetabolites used in the treatment of 
a wide variety of hematological malignancies and solid tumors. Upon being metabolized 
to their active triphosphate form, these agents are incorporated into DNA. Among other 
molecular targets, their incorporation may lead to activation of base excision repair 
(BER) pathway. The molecular mechanism of BER recognition and repair of the 
incorporated fludarabine has not yet been elucidated. The main focus of this research was 
to study the involvement of BER pathway in the response to fludarabine induced DNA 
damage. Also, the possibility of enhancing antineoplastic activity of fludarabine by 
inhibition of BER (e.g. methoxyamine) was investigated.   
 Firstly, capacity of uracil DNA glycosylase to recognize and excise incorporated 
fludarabine was established. Secondly, the formation of abasic (AP) sites after 
fludarabine treatment was confirmed in different human cancer cell lines. These results 
demonstrated that incorporated fludarabine, acting as an abnormal base in DNA, initiates 
BER. 
 The possibility to enhance fludarabine-induced damage by inhibiting BER was 
then considered. Exposure of cells to fludarabine and methoxyamine (MX) combined 
regimens caused increased apoptosis, clonogenic death, upregulation of some key BER 
iv 
proteins, enhanced DNA strand breaks. It also enhanced anti-tumor effects in human 
xenografts. This response of cells to fludarabine plus MX was due to MX binding to the 
ara-AP sites formed by fludarabine, thus turning the repairable DNA damage into lethal 
lesions. In addition, mitochondrial DNA was found to be targeted by fludarabine and 
fludarabine plus MX. Apoptotic signaling from nuclear and mitochondrial DNA damage 
triggered mitochondrial mediated cell death during BER disruption by MX. 
 The modulation of fludarabine cytotoxicity by manipulating BER via MX was 
analyzed in a similar series of experiments using primary lymphocytes obtained from 
CLL patients. MX enhancement of activity of fludarabine was confirmed; the results 
showed that CLL cells were significantly more sensitive to the fludarabine in combination 
with MX as assayed by cytotoxicity, apoptosis, and levels of DNA damage.  
 Collectively, these results show that the combination of fludarabine plus MX 
represents a potential new clinical targeted therapy.  
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CHAPTER I   
INTRODUCTION: FLUDARABINE, BASE EXCISION REPAIR AND 
CELL DEATH MECHANISMS OVERVIEW 
 
 
1.1.  Fludarabine 
1.1.1. Structure and development 
The need of new therapeutic strategies in the treatment of leukemia and 
lymphoma led to development of the active agent, cytarabine (ara-C) and set the stage for 
development of other nucleoside analogues. Vidarabine (ara-A), an adenosine analog, 
was proven clinically ineffective due to rapid metabolic clearance by adenosine 
deaminase. This rapid inactivation of vidarabine by deamination suggested the need for 
structural modifications that will confer resistance to deamination while maintaining the 
antineoplastic potential. The addition of a fluorine substitute at the position 2 of adenine 
nucleoside renders resistance to deaminase. Montgomery and Hewson were the first ones 
to synthesize 9-β-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) [1-3]. Because F-ara-A 
was relatively insoluble, its 5’-monophosphate (Fludarabine, Berlex Laboratories, 
Richmond, CA) had been used in clinical settings (Figure 1-1). 
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Figure 1-1.  
Structures of Adenosine, Ara-adenosine and Fludarabine 
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 The monophosphate formulation of fludarabine is rapidly and quantitative 
dephosphorylated to the nucleoside F-ara-A. This first pass metabolism is attributed to 
5’-nucleosidase activities of erythrocytes and endothelial cells (Figure 1-2) [4]. F-ara-A is 
actively taken into cells by nucleoside transport systems (hENT, hCNT) [5]. Inside the 
cells, F-ara-A is rephosphorylated to monophosphate and subsequently to the diphosphate 
and triphosphate (Figure 1-2). It has been shown that deoxycytidine kinase is the major 
kinase for phosphorylation to the monophosphate [6], while adenylate kinase and 
nucleoside diphosphate kinase are the enzymes responsible for the subsequent 
phosphorylation steps. The triphosphate, F-ara-ATP is the main metabolite of fludarabine 
and the only known to have cytotoxic activity.  
 4
  
 
 
 
 
 
 
 
Figure 1-2 
Transport and metabolism of Fludarabine 
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1.1.2. Mechanisms of action 
1.1.2.1. Target: DNA polymerase 
The principal pharmacodynamic effect of fludarabine is inhibition of DNA 
synthesis, by targeting multiple enzymes at different steps in this process. The central 
component of the DNA synthesis machinery is the DNA polymerase. Early reports 
demonstrate that DNA polymerases are targets for the action of F-ara-ATP. F-ara-ATP 
does not directly inhibit the enzymes, but its inhibitory properties are achieved after 
incorporation into DNA [7]. The presence of a thymidylate in the template strand leads to 
incorporation of F-ara-ATP competitively with dATP. When one F-ara-A was 
incorporated into DNA strand , the DNA polymerases are inhibited or forced to pause at 
that specific site in the DNA strand. This inhibitory property makes fludarabine a chain 
terminator. Studies using cell-free systems have shown that significant percentage of F-
ara-AMP was at the terminal position in DNA extracted from cells incubated with [3H]F-
ara-A [8]. Human DNA polymerase α, β, γ and ε are the main polymerases that are 
sensitive to inhibition by F-ara-ATP [9,10]. 
 In addition, the stability of F-ara-AMP at the 3’ end suggests that it is resistant to 
the proof-reading activities of DNA polymerases. DNA polymerase ε has been studied 
for its associated 3’ to 5’ exonuclease activities. DNA polymerase ε has a 35 fold greater 
affinity for F-ara-AMP-terminated DNA than for DNA terminated by deoxyadenosine 
monophosphate. Removal of F-ara-AMP was slow and the excision of the subsequent 
nucleotide was not observed. The velocity of the excision reactions was lower when 
compared with the rate of deoxyadenosine monophosphate [11]. Thus, the polymerization 
 7
and the proof reading activities associated with DNA polymerases are inhibited by the 
presence of F-ara-A in the DNA strand.  
1.1.2.2. Target: Ribonucleotide reductase 
Ribonucleotide reductase is the central and rate-limiting enzyme involved in the 
synthesis of deoxyribonucleotides, the building blocks for DNA synthesis. Incubation of 
cells with F-ara-A leads to reduction in cellular concentrations of deoxynucleotides and 
DNA synthesis concomitant with increase in F-ara-ATP levels [12-14]. Fludarabine is an 
allosteric inhibitor of ribonucleotide reductase resulting in reduction of the cellular 
concentrations of deoxycytidine triphosphate (dCTP), deoxyadenosine triphosphate 
(dATP) and deoxyguanosine triphosphate (dGTP) except for the concentrations of 
deoxythymidine triphosphate (dTTP). Incubation of purified ribonucleotide reductase 
with F-ara-ATP led to decreased enzymatic activity due to interaction with global 
allosteric inhibitory site of the enzyme [7,9].  
F-ara-ATP competes with dATP for incorporation into DNA strand, thus 
reduction in dATP levels results in self-potentiation. Furthermore, fludarabine is also 
involved in a different metabolic self-potentiation mechanism involving deoxycitidine 
kinase. This enzyme is regulated by the levels of deoxynucleotides, mainly dCTP. Due to 
decrease in the dCTP levels, the activity of deoxycytidine kinase is enhanced that will 
result in increased phosphorylation rate of F-ara-A [15,16]. This is the rate limiting step 
in accumulation of the cytotoxic metabolite, F-ara-ATP.  
1.1.2.3. Target: Inhibition of DNA primase 
DNA replication is a fundamental process using different mechanism of synthesis 
for each DNA strand, involving separate set of enzymes. Replication of the leading strand 
 8
(5’ to 3’ direction) is a continuous process that uses either polymerase δ or ε. In contrast, 
the replication of the lagging strand (3’ to 5’ direction) occurs discontinuously by the 
sequential joining of the Okazaki fragments (200 nucleotides). Along the lagging strand's 
template, DNA primase builds RNA primers in short bursts. DNA polymerases α are then 
able to use the free 3' OH groups of the RNA primers to synthesize DNA in the 5'→3' 
direction. Once the Okazaki fragments are completed, the RNA fragments are then 
removed (different mechanisms are used in eukaryotes and prokaryotes). DNA ligase 
then joins the deoxyribonucleotides together, completing the synthesis of the lagging 
strand. It was previously reported that F-Ara-ATP inhibits the function of DNA primase. 
More specifically, F-ara-ATP is a better substrate for this enzyme that the natural 
substrate, adenosine triphosphate, leading to termination of RNA primer. Additonally, 
DNA polymerase α is unable to add deoxynucleotides to the RNA primers terminated by 
F-ara-AMP [17-19]. 
1.1.2.4. Target: Inhibition of DNA ligase I 
DNA ligase I has a role in both replication and repair of DNA. DNA ligase I seal 
a single-stranded nick in a double-stranded DNA by catalyzing the formation of 
phosphodiester bond between the 3’-hydroxyl of one piece of DNA with the 5’-phosphate 
of an adjacent DNA. The enzymatic activity involves several steps. First, DNA ligase I 
interacts with ATP to form a ligase-AMP complex with the release of pyrophosphate. In 
the next step, nicked DNA interacts with the ligase-AMP complex to form a DNA-AMP 
complex in which AMP is linked to the 5’-terminus of the nick. In the third step, a 
phosphodiester bond is formed across the nick and AMP is released from the enzyme. 
Fludarabine inhibits this process at two steps. Firstly, F-ara-ATP interacts directly with 
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DNA ligase I to form a complex. This inhibition persisted even after removal of free F-
ara-ATP from treated enzyme. Secondly, the enzymatic activity of the DNA ligase I was 
inhibited by the reaction with a DNA strand terminated in F-ara-AMP. The rate of the 
ligation, using this substrate was 10 % of that of normal DNA. This data indicate that the 
DNA strand with F-ara-AMP is a poor substrate for DNA ligase I [20].  
1.1.2.5. Inhibition of RNA synthesis 
Fludarabine is been shown to incorporate not only in DNA, but also in RNA, as a 
consequence is inhibitory to RNA synthesis. The inhibition of RNA synthesis is 
dependent on concentration of F-ara-ATP [21]. RNA synthesis is enzymatically achieved 
by RNA polymerase I, II and III. Incubation of human lymphoblast with fludarabine 
resulted in incorporation of F-ara-A preferentially into poly (A+) RNA fraction. This 
incorporation into RNA resulted in premature termination of RNA transcript and 
subsequently impaired the protein synthesis. 
1.1.3. Fludarabine in CLL: rationale for combination therapies 
Fludarabine monotherapy is an established regimen for treatment of chronic 
lymphocytic leukemia (CLL) achieving superior remission rate compared with older 
treatment regimens containing alkylating agents or corticosteroid [22,23]. CLL is the 
most common hematological malignancy in western world. CLL arises from a malignant 
clone of B cells with a characteristic phenotype. The disease encompasses a diversity of 
clinical symptoms which translate into variable prognosis and survival. Complete 
response rates with fludarabine as single agents are 15-20 % in previously treated patients 
and 40-50 % in newly diagnosed ones. However, this response rates are low and usually 
transient, with all patients eventually experience a relapse [24,25]. Because fludarabine is 
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not curative when used as monotherapy, efforts are made to improve fludarabine efficacy 
by establishing a rational basis for combination with other drugs. Both biochemical and 
biological modulation have been studied. Biochemical modulation of cytarabine 
metabolism by fludarabine through up-regulation of deoxycytidine kinase activity led to 
promising results [26]. In addition, by biological modulation, the remission rate of 
patients treated with combined therapy, fludarabine plus granulocyte colony stimulating 
factor (G-CSF), was greater (63 %) than therapy with fludarabine alone (41 %) [27]. 
Several other combined regimens were extensively studied.  
1.1.3.1. Combinations with DNA-damaging agents 
The overall concept of combining DNA damaging agents with fludarabine relays 
on the hypothesis that fludarabine inhibits the nucleotide excision repair process (NER) 
induced by the damaging agents and thus enhances the cytotoxicity of these compounds.  
Cyclophosphamide. Combination of fludarabine with cyclophosphamide has been 
examined in 10 clinical trials. For example, in a phase III comparative trial, 207 
treatment-naive patients with advanced CLL were treated with either fludarabine or in 
combination with cyclophosphamide. The combination regimens resulted in significantly 
higher overall response (OR) (94 versus 85 % with fludarabine alone) and complete 
response (CR) (21 versus 9 % respectively) [28]. The main disadvantage associated with 
this combination was the myelosuppression (neutropenia, thrombocytopenia and anemia). 
Chlorambucil. Fludarabine plus chlorambucil was evaluated in four clinical trials, two 
phase I/II trials and two large phase III trials. Collectively, the results from these studies 
suggest that the combination does not produce a significant improvement in response rate 
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or survival compared with fludarabine alone. Furthermore, the combined regimen was 
associated with severe adverse effects [29,30].  
Cyclophosphamide and mitoxantrone. The combination of fludarabine with 
cyclophosphamide and mitoxantrone was assed in one clinical trial. The OR was 78 %, 
including 50 % CR and 28 % PR, but the incidences of myelosuppression and infection 
were significantly higher.  
Prednisone. Two studies of CLL patients were used to evaluate the efficacy of 
fludarabine plus prednisone. The results show that the combination resulted in an OR of 
80 %, no significant different from fludarabine alone (80 %). CR rate for fludarabine plus 
prednisone was 23 %, significantly lower than for fludarabine alone (38 %). Together, 
these results showed that fludarabine plus prednisone is no more effective than 
fludarabine alone [31]. 
Other chemotherapeutic agents. Seven trials have investigated fludarabine in 
combination with six other chemotherapeutic agents. Fludarabine plus mitoxantrone did 
not markedly increase the response rate compared to fludarabine alone (OR was 77 % 
and CR was 20 %) [32]. Fludarabine plus doxorubicin demonstrated no therapeutic 
benefits and increased rates of opportunistic infections [33]. In contrary, a higher 
response rate was achieved in a phase II study with fludarabine and epirubicin. (OR of 92 
% and CR of 40 %). Also, adverse effects associated with this combined treatments were 
relatively mild. These results were also confirmed in a phase III randomized trial (OR of 
89% and CR of 26 %) [34]. There are three other fludarabine combination regimens 
which have proved to be less effective than monotherapy with fludarabine: cytarabine, 
cisplatin and dexamethasone [35-37]. 
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 Collectively, these studies demonstrated that when fludarabine is given as a 
component of combination therapies, clinical relevant effects are sometimes observed, 
but also show that there is a need for further, more effective combinatory regimens. 
 
1.2. Base excision repair pathway 
1.2.1. Overview 
Base excision repair is the major system responsible for removal of damaged 
DNA bases and repair of DNA single strand breaks generated spontaneously or induced 
by exogenous DNA damaging factors such as ionizing radiation and alkylating agents 
[38]. In brief, BER involves: (i) damaged base excision, (ii) incision at the resulting 
abasic (AP) site, (iii) replacement of missing nucleotide, and (iv) sealing of the resulting 
nick. Excision repair of the damaged base is initiated by a specific DNA glycosylase, the 
enzyme responsible for the recognition and removal of damaged base by hydrolyzing the 
glycosylic bond (the bound linking the base residue to the DNA sugar phosphate 
backbone). Further, the AP site is recognize by AP endonuclease (APE) that will cleave 
the phosphodiester bond 5’ to the AP site generating an single strand break containing a 
5’-sugar phosphate. Several proteins are involved in processing of the modified 3’and 5’-
ends: DNA polymerase β (pol β), polynucleotide kinase (PNK), APE and aprataxin. After 
restoring conventional 3’-hydroxyl and 5’-phosphate strand breaks ends, repair is 
accomplished by either short or long -patch pathway. In the major BER pathway, short-
patch repair, pol β adds one nucleotide to the 3’-OH end of the strand break, thus filling 
one nucleotide gap created during repair. The DNA ligase IIIα-XRCC1 heterodimer seals 
the DNA end and completes the repair process (Figure 1-3) [39,40]. The minor BER 
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pathway, long-patch acts to repair AP sites that have the sugar residue modified, e.g. 
oxidized or reduced [41]. To initiate this pathway, pol β first adds one nucleotide to the 3’ 
end of the nick and than pol δ and ε add a few more nucleotides to generate part of a 
single-stranded flap structure containing a 5’ sugar phosphate. This flap structure is 
recognized and excised by flap endonuclease 1 (FEN1) and the DNA is finally ligated by 
DNA ligase I. FEN1 activity is stimulated by proliferating cell nuclear antigen (PCNA) 
[42]. Alternately, the repair process can be catalyzed by pol δ plus PCNA [41].  
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Figure 1-3 
The base excision repair pathway [39] 
The proteins believed to be responsible for various reaction steps are shown. The detailed 
mechanism is described in text. Short-patch BER is responsible for a single nucleotide 
repair, whereas in long-patch BER, two to ten nucleotides are replaced.  
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Base excision repair proteins: 
DNA glycosylases.  DNA glycosylases are responsible for initiating BER by catalyzing 
hydrolysis of the C1’-N glycosylic bond to the damaged base and by removing the base, 
generating an AP site. Ten glycosylases have been identified to have a role in mammalian 
BER and their specificities are summarized in Tabel 1-I. DNA glycosylases can be 
divided in two classes based on their mechanistic activity: mono-functional (i.e. 
glycosylase activity only) such as UDG and bi-functional (i.e. glycosylase and β-lyase 
activities) such as hOGG1 [43].  
 
TABLE 1-I.  Mammalian DNA Glycosylases and their substrates  
Glycosylases Bifunctional ? Substrates 
UNG2 No U, 5FU. 
Smug1 No U, OHMeU 
TDG No U:G, T:G, ethenoC 
MBD4 No U:G, T:G in CpG sites 
OGG1 Yes 8oxoG:C, FapyA, FapyG 
MYH No A:8oxoG 
NTH1 Yes Oxidised and fragmented pyrimidines (e.g. Tg, DHU) 
Fapy 
AAG (MPG) No 3-meA, 7-meG, ethenoA, ethenoG, hypoxanthine 
NEIL 1  Yes FapyA, FapyG, dihydrouracil, thymine glycol, 8-
oxoG (low) 
NEIl2 Yes cytosine oxidation products (5-OHU, DHU) 
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The crystal structures of many of the DNA glycosylases have been elucidated. They show 
some similarities which suggests a common mode of action. The glycosylases gently 
pinch the DNA while scanning it resulting in bending of DNA at the site of instability 
caused by mismatching. This DNA bending combined with pushing from the enzyme 
makes mismatch base to flip out of the DNA and to enter the binding site of the enzyme. 
While in the binding site, the base bond to the sugar is cleaved by the enzyme. In Figure 
1-4 is presented the enzymatic mechanism of UDG [44].  
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Figure 1-4 
Proposed mechanism for UDG cleavage of N-glycosyl bond [44] 
The uracil base dissociates leading to an oxocarbenium cation intermediate (1 → 2). 
Subsequent attack by water produces an apurinic/apyrimidinic (AP) site (2 → 3).  
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AP endonucleases.  An important step in BER pathway involves the cleavage of the AP 
site by APE. APE is a multifunctional enzyme that is not involved only in BER, but also 
functions as a reduction-oxidation factor to maintain transcription factors in an active 
state. Extensive studies showed that mice nullzygous for APE gene are embryonic lethal 
[45] and downregulation of APE levels in human cells using RNAi leads to accumulation 
of AP sites, inhibiting DNA replication and generating apoptosis [46]. APE cleaves the 
phosphodiester bonds in an Mg2+-dependent manner, leaving a 3’-hydroxyl group and a 
5’-deoxyribose phosphate (dRP) group flanking the nucleotide gap.  
BER DNA polymerases. The presence of an intermediate containing a 3’-hydroxyl 
group acts as a substrate for DNA polymerase. In the short-patch BER pathway, DNA 
synthesis is carried out by pol β [47,48]. Pol β contains two domains: a C-terminal 
polymerase domain and an N-terminal dRP domain. Both domains are required for short-
patch BER. Processing of the single-strand breaks resulted by dRP lyase activity of pol β 
is carried out through catalysis of a β-elimination reaction. This reaction is followed by a 
polymerase activity to fill the nucleotide missing [49]. Pol β lacks any intrinsic proof-
reading activities. Pol β is ubiquitinously express in all tissues. It is also expressed 
constitutively and without demonstrable cell-cycle dependence. The importance of this 
enzyme for the cells was demonstrated using studies in mice. They showed that mice 
nullizygous for pol β are non-viable and die early in embryogenesis [50].  
DNA ligases. DNA ligase I and DNA ligase III are the main ligases involved in BER. 
DNA ligase III exists as two isoforms: DNA ligase IIIα and DNA ligase IIIβ [51]. The 
enzymatic activity of DNA ligase IIIα is dependent on interaction with XRCC1. DNA 
ligase I is involved in long-patch BER pathway, but also plays a role in DNA replication 
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[51]. Human cells containing DNA ligase I show hypersensitivity to DNA-damaging 
agents [52].  
XRCC1. XRCC1 is a multi-domain protein with an N-terminal DNA binding domain 
and two BRCT (BRCA1 C-terminus) motifs. BRCT I contains the site of interaction with 
PARP1 and BRCT II is involved in interaction with DNA ligase IIIα [53]. The nick-
binding N-terminal domain of XRCC1 interacts with pol β, forming a tertiary complex 
with the polymerase and nicked DNA. Cells deficient in XRCC1 show partial defect in 
BER efficiency when compared to wild type. The importance of the XRCC1 gene for 
cellular functioning is underlined by the fact its targeted knockout results in embryonic 
lethality [54]. XRCC1 interacts also with PARP1, APE and PCNA.  
Poly(ADP-ribose)polymerase, Polynucleotide kinase, Aprataxin. The role of PARP1 
in BER is to bind to incised AP sites before any other repair proteins. In vitro repair 
reactions carried out on absence of PARP1 result in increased nucleolytic degradation of 
BER intermediates, thus it suggests that PARP1 functions to protect strand breaks and 
repair intermediates from degradation or recombination [55]. Additionally, it has been 
reported that the genome of PARP1 null mice shows an increased incidence of deletion 
mutations upon DNA damage.  
Polynucleotide kinase (PNK) in an enzyme involved in the processing of 5’-phosphate 
and 3’-hydroxyl ends at single strand breaks. As part of the repair pathway, PNK 
interacts with XRCC1, DNA ligase IIIα and pol β [56].  
Aprataxin is a member of the HIT superfamily of nucleotide hydrolases/transferases. 
Aprataxin interacts with XRCC1 and it is involved in the resolution of abortive DNA 
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ligation intermediates by catalyzing the release of adenylate groups covalently linked to 
5’-phosphate termini at single strand nicks [57]. 
1.2.2. Targeting BER to overcome drug resistance 
Most chemotherapeutic agents cause cell death by damaging DNA. Some of this 
agents, initially effective, develop resistance through repair capacities of the cancer cells. 
Various preclinical studies suggest that BER represents an important target for anticancer 
therapy as its inhibition has been shown to sensitizes cells to cytotoxic effects of different 
alkylating agents. Several approaches have been developed. One direction was focused 
on inhibiting BER by targeting APE. Up to date, two chemical compounds were isolated 
(CRT0044876 and lucanthone) and shown to have APE inhibitory characteristics. By 
combining these compounds with alkylating agents or methylating agents, significant 
increase in cytotoxic activity against ovarian cancer cells has been measured [58,59]. A 
second direction was focused on PARP1 inhibition. Even though the role of PARP1 in 
BER is not fully understood, inhibition of PARP1 leads to inhibition of DNA repair and 
promotes apoptosis in cancer cells. Currently, several PARP1 inhibitors are evaluated in 
clinical trials in combination with certain anticancers agents (Tabel 1-II). One example of 
this combined therapy is TMZ plus PARP1 inhibitor. It has been shown that when 
PARP1 is inhibited, it remains bound to the SSB created by TMZ which triggers 
apoptosis [60]. PAPR1 inhibitors enhance the cytotoxicity of DNA topoisomerase I 
inhibitors, irinotecan and topotecan. They also enhance the cytotoxic effect of 
radiotherapy, both in vitro and in vivo [61]. Several other combination strategies for 
PARP1 inhibitors are under investigation.  
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TABLE 1-II.  PARP inhibitors currently in clinical trials 
PARP inhibitor Phase of trial Subject group 
AG-014699 I, II Patients with malignant melanoma 
KU 59436 I Patients with advanced solid tumors 
INO-1001 IB Patients with advanced solid tumors 
INO-1001 I Patients with glioblastoma multiforme 
BSI-201 I Patients with advanced solid tumors 
GPI 21016 I Patients with advanced solid tumors 
ABT-888 Pilot study Patients with advanced solid tumors and 
lymphoid malignacies 
 
A more promising strategy to enhance cytotoxic effect of chemotherapeutic agents by 
targeting BER is the use of a small molecule, methoxyamine (MX) and its derivatives. 
1.3. Methoxyamine 
1.3.1. Mechanism of action 
Methoxyamine (MX) has been extensively studied as an inhibitor of BER. The action 
of MX in inhibiting BER has been demonstrated (Figure 1-5): (a) MX binds to the 
aldehyde group of the tautomeric open ring form of deoxyribose generated after removal 
of the abnormal base by DNA glycosylase; (b) the reaction of MX with AP sites is faster 
than APE reaction with the same site; (c) MX-bound AP sites reduce the APE cleavage 
of the DNA backbone by more than 300-fold compared with the cleavage of the normal 
AP site [62-65]. Chemotherapeutic agents such as temozolomide (TMZ) and 1,3-bis-(2-
chloroethyl)1-nitrosurea (BCNU) form AP sites due to removal of the drug-induced 
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methylated purine by DNA glycosylase. BCNU alkylates DNA predominantly ( >90 %) 
at N7 position of guanine. Repair of these lesions involves formammidopyrimidine-DNA 
glycosylase (FPG) and 8-oxoguanine-DNA glycosylase (OGG1). Temozolomide 
treatments result in methylation of N7 position of guanine (70 %) and of N3 position of 
adenine (4 %). These lesions are removed from DNA by methylpurine glycosylase 
(MPG) leading to formation of AP sites. Blocking the repair of these AP sites with MX 
leads to accumulation of these cytotoxic sites (MX-bound AP-sites) in DNA [65]. MX 
has been shown to augment the cytotoxicity of several DNA damaging agents in vitro and 
also in xenograft studies [66,67]. MX is able to potentiate cytotoxicity in both MMR-
proficient and MMR-deficient cells [60]. MX is also able to overcome other resistance 
factors such as the loss of p53 tumor suppressor function [65]. An example of effective 
enhancement of cytotoxicity by MX is the combination with TMZ. This combined 
treatment regimen was extensively studied in vitro and in vivo. In vivo, MX enhanced 
antitumor effect of TMZ in several colon cancer cell lines that was associated with 
significant apoptotic cell death and severe chromosomal aberrations (sister chromatin 
exchange, DNA breakage and aneuploidity) [66]. In vitro, MX binds to the AP sites 
formed by TMZ treatments to form MX-bound AP-sites. These sites cannot be repaired 
by APE leading to apoptotic cell death. One molecular mechanism of cell death mediated 
by MX-bound AP-MX is conversion of topoisomerase II into biotoxin, resulting in 
enzyme-mediated DNA scission and cell death. [68]. MX was also shown to enhance 
cytotoxicity of 5-iodo-2’deoxyuridine (IdUrd), a halogenated thymidine analog. [69]. 
Such results led to BER modulation to augment clinical response of cytotoxic agents 
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currently used in the clinic. A Phase I clinical trial of MX in combination with TMZ is 
currently in progress. 
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Figure 1-5 
Methoxyamine binds to the AP site and blocks APE cleavage [65] 
Methoxyamine reacts with the aldehyde moiety of the open-ring form of the AP site 
generated after removal of the damaged base by a DNA glycosylase. The MX-bound AP 
sites formed are refractory to cleavage by APE. 
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1.4. Apoptotic cell death pathways 
Apoptosis is in general characterized by distinct features and energy-dependent 
biochemical mechanisms. Apoptosis is considered a vital component of normal cell 
turnover, proper development and function of immune system, hormone-dependent 
atrophy, embryonic development and chemical-induced cell death. The ability to 
modulate the death of a cell it is recognized for its tremendous therapeutic potential. To 
date, numerous studies have shown that there are two main apoptotic pathways: the 
extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway. These 
pathways converge on the same terminal, execution pathway [70]. 
1.4.1. Extrinsic (death receptor) pathway 
The extrinsic pathway is characterized by transmembrane-receptor-mediated 
interactions. The key players are the death receptors that are members of the tumor 
necrosis factor (TNF) receptor gene superfamily. All members share a similar 
cytoplasmatic domain called the “death domain” which plays an important role in 
transferring the death signaling from the surface to intracellular signaling. Several ligands 
and corresponding death receptors have been studied: FasL/FasR, TNFα/TNFR1, 
Apo3L/DR, Apo2L/DR4 and Apo2L/DR5 [71,72]. Upon ligand binding, cytoplasmatic 
adaptor proteins are recruited and will bind the receptor. These adaptor proteins will 
associate with procaspase-8 through dimerization of the death effector domain. Following 
this association, death-inducing signaling complex (DISC) is formed, resulting in auto-
catalytic activation of procaspase-8 [73]. Once caspase 8 is activated, the execution phase 
of apoptosis is triggered (Figure 1-6).  
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Figure 1-6 
The extrinsic apoptotic pathway [74] 
The extrinsic pathway begins outside the cell through the activation of specific pro-
apoptotic receptors on the cell surface by specific molecules known as pro-apoptotic 
ligands. The intracellular domains of these receptors, known as the 'death domains', bind 
to the adaptor protein Fas-associated death domain (FADD), leading to the assembly of 
the death-inducing signaling complex, or DISC, and recruitment and assembly of initiator 
caspases 8 and 10. Caspases 8 and 10 are stimulated and undergo self processing, 
releasing active enzyme molecules into the cytosol, where they activate caspases 3, 6, and 
7, thereby converging on the intrinsic pathway. 
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1.4.2. Intrinsic (mitochondrial) pathway 
The intrinsic signaling pathway involves a variety of stimuli that result in 
intracellular signals that act directly on targets within the cell and are mitochondrial-
initiated events. These stimuli cause changes in the inner mitochondrial membrane that 
will lead to opening of the mitochondrial permeability transition (MPT) pore, loss of the 
mitochondrial transmembrane potential and release of the two groups of sequestered pro-
apoptotic proteins from the intermembrane space to the cytosol [75]. The first group 
contains cytochrome C, Smac/Diablo and a serine protease Htr2/Omi. Cytochrome c 
binds and activates Apaf-1 and procaspase-9, forming a complex called “apoptosome” 
(Figure 1-7) [76]. This complex formation leads to caspase-9 activation. Additionally, 
Smac/Diablo and Htr2/Omi promote apoptosis by inhibiting IAP (inhibitors of apoptosis 
proteins). The second group of pro-apoptotic proteins, AIF, endonuclease G and Caspase-
activated DNase (CAD), are release late from mitochondria, after the cell has committed 
to die. AIF translocated to nucleus and cause DNA fragmentation into 50-300 kb pieces 
and condensation of peripheral nuclear chromatin, known as stage I condensation [77]. 
Endonuclease G translocates to nucleus as well where it cleaves nuclear chromatin to 
produce oligonucleosomal DNA fragments [78]. CAD translocates to nucleus where 
leads to DNA fragmentation and a more advanced chromatin condensation. The control 
and regulation of these mitochondrial events occurs through members of Bcl-2 family 
proteins. These proteins can be either pro-apoptotic or antiapoptotic. To date, 25 genes 
have been identified. The antiapoptotic proteins include Bcl-2, Bcl-xl, BAG, Bcl-xs. The 
pro-apoptotic proteins include Bcl-10, Bax, Bad, Bim, Bik [79].  
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Figure 1-7 
The intrinsic (mitochondrial) apoptotic pathway [74] 
The intrinsic pathway is initiated from within the cell. This is usually in response to 
cellular signals resulting from DNA damage. This pathway involves release from the 
mitochondria of pro-apoptotic proteins that activate caspase enzymes, which ultimately 
trigger apoptosis.  
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The intrinsic and extrinsic pathways converge to execution phase. This phase is 
represented by the activation of execution caspases. Execution caspases activate 
cyoplasmic endonuclease which degrades nuclear material, and protease that degrade the 
nuclear and cytoskeletal proteins. Executioner caspases are: caspase-3, caspase-6 and 
caspase-7. These caspases cleave various substrates such as PARP, cytokeratins, the 
plasma membrane cytoskeletal protein alpha fodrin, and other, that cause the 
morphological and biochemical changes in apoptotic cells [80].  
1.4.2.1. Mitochondrial DNA damage 
Mitochondrial DNA (mtDNA) is a circular double-stranded genome, consists of 
15,000-17,000 base pairs (bp) that codes for 13 subunits of the oxidative phosphorylation 
system, 2 ribosomal RNAs (rRNAs), and 22 transfer RNAs (tRNAs) (Figure 1-8) [81]. It 
is present in 100-10,000 copies per cells. MtDNA consists of predominantly of coding 
DNA with exception of an 1100 bp long region that has mainly regulatory functions.  The 
DNA polymerase gamma (pol γ) is used for the replication of mtDNA. The replication is 
in a D-loop mode due to different origins of replication on the two strands. One strand 
begins to replicate first, displacing the other strand. This process continues until 
replication reaches the origin of replication of the other strand, at which point the other 
strand begins to replicate in the opposite direction.  
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Figure 1-8 
Mitochondrial DNA [81] 
Human mtDNA encodes 13 polypeptides: 7 subunits - ND1, ND2, ND3, ND4, ND4L, 
ND5, and ND6 - of Complex I (NADH-Coenzyme Q oxidoreductase); 1 subunit - 
cytochrome b - of Complex III (CoQ-cytochrome c oxidoreductase), 3 subunits - COX I, 
COX II, and COX III - of Complex IV (cytochrome c oxidase, or COX), and 2 subunits - 
ATPase 6 and ATPase 8 - of Complex V (ATP synthase). It also encodes 2 rRNAs (in 
green) and 22 tRNAs (in blue). 
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Mitochondrial DNA transcription involves mtRNA polymerase, mitochondrial 
transcription factor A and mitochondrial transcription factors B1 and B2. The proteins 
assemble at the mitochondrial promoters and begin transcription. MtDNA has three 
promoters, H1, H2 and L (heavy strand 1, heavy strand 2 and light strand promoters. The 
H1 promoter transcribes the entire heavy strand, the L promoter transcribes the entire 
light strand, while H2 promoter causes transcription of the two mitochondrial rRNAs.  
MtDNA is very susceptible to damage from various sources such as free radicals 
and chemotherapeutic agents which will lead to deletions, rearrangements, other 
mutations or activation of apoptosis. Recent evidence suggests that mitochondria contain 
DNA repair mechanisms.  There is evidence for base excision repair (BER), direct 
damage reversal, mismatch repair, and recombinational repair mechanisms in 
mitochondria, while nucleotide excision repair (NER), as we know it from nuclear repair, 
is not present [82]. 
1.4.2.2. Mitochondrial DNA base excision repair pathway 
     A simplified BER in mitochondria has been established but has not been 
extensively characterized. Several BER enzymes such as uracil DNA glycosylase [83] 
and AP endonuclease [84] have been detected in mitochondria (Figure 1-9). The 
replication polymerase in mitochondria is γ (pol γ), and it has been demonstrated that 
purified pol γ can also serve as a repair polymerase in mitochondria [85-87]. The ligase 
involved in mitochondrial BER is believed to be an alternate splice variant of nuclear 
DNA ligase III [84]. The pathway includes four distinct steps: lesion removal by a 
glycosylase, abasic site processing by an AP endonuclease, insertion of a new nucleotide 
by polymerase γ and ligation of the broken strand by DNA ligase. 
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Figure 1-9 
The short-patch mitochondrial BER [87] 
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CHAPTER II   
STATEMENT OF OBJECTIVES 
 
 Fludarabine is a widely used anti-tumor agent for the treatment of indolent 
lymphoproliferative disorders. The inhibition of DNA replication via incorporation of F-
ara-ATP into DNA and subsequent chain termination is thought to be a significant 
mechanism leading to fludarabine-induced cell death. However, the molecular aspects of 
the cytotoxic action of fludarabine are not completely understood.   
 This work aims to expand the knowledge on the biochemical mechanisms of 
fludarabine-induced cytotoxic effects. Fludarabine, a purine base analog, incorporates 
into DNA and possibly acts as an abnormal base, triggering the activation of base 
excision repair (BER) system. BER entails the combined effort of several repair proteins 
(DNA glycosylases) that recognize and excise specific DNA damages, converting diverse 
base lesions into a common intermediate, apurinic/apyrimidinic (AP) sites. Eventually the 
damaged moiety is replaced with a normal nucleotide and DNA is restored back to its 
original state. The potential involvement of BER (essential for both, nuclear and 
mitochondrial DNA) in processing incorporated fludarabine was not previously 
documented or explored. Moreover, once initiated BER could account for resistance to 
fludarabine, since a functional active BER should be able to recognize and repair the 
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specific DNA damage induced by the incorporated drug. It would be then only reasonable 
to predict that BER inhibitors – e.g. methoxyamine (MX) – could enhance antineoplastic 
activity of fludarabine and thus, a combination of fludarabine plus MX might represent a 
new and effective therapeutic strategy. To test this series of suppositions, the following 
specific aims were devised: 
 
1. To demonstrate that BER enzymes are capable to recognize and initiate removal 
of fludarabine incorporated into DNA (Chapter 3) 
 The working hypothesis for this aim is that at least one of the members of DNA 
glycosylase family can recognize and excise incorporated fludarabine. An in vitro 
screening for DNA glycosylase activity, employing various purified enzymes or whole 
cell extracts and a synthesized 40-mer oligonucleotide substrate that contains fludarabine, 
is performed. Subsequent kinetic studies to characterize the enzymatic activity of selected 
glycosylase are carried out.  
 Identifying the glycosylase potentially implicated in fludarabine recognition is 
significant for two main reasons: (i) it sustains the possibility that BER is involved in 
processing incorporated fludarabine and (ii) it is critical for the subsequent molecular 
studies, since more targeted experiments can be devised to investigate the eventual role of 
BER in modulating fludarabine action. 
 
2. To demonstrate BER involvement in fludarabine-induced damage and to 
investigate the effect of MX on blocking the repair process (Chapter 4)  
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 Based on the structural similarities with the normal base and the primary action of 
fludarabine to incorporate into DNA, the tested hypothesis is that incorporated 
fludarabine, acting as an abnormal base in DNA, initiates BER. This hypothesis is 
verified in cancer cell lines that are expressing or not the glycosylase identified in 
specific aim 1. The experimental approach involves (i) a correlation of AP site formation 
with concentrations of fludarabine  (first step in BER) and (ii) an examination of 
expression of key BER proteins in a strategy of treatments with fludarabine alone. 
 Additionally, a new possibility to enhance fludarabine-induced damage by using 
MX in combination with fludarabine is proposed. Hypothesis that MX is able to bind to 
fludarabine-induced AP sites, thus further blocking the repair pathway is tested in human 
tumor cell lines with different repair status and in several human tumor xenografts, by 
assessing the toxicity induced by fludarabine alone or in combination with MX.  
 Two important findings are aimed here: (i) a first demonstration that in cells BER 
can process incorporated fludarabine and (ii) insights into a new and promising drug 
combination (fludarabine plus MX). 
   
3. To delineate the contribution of mitochondrial apoptotic pathway in cell death 
after fludarabine and MX exposure (Chapter 5) 
 The working hypothesis is that mitochondrial DNA is a target for fludarabine and 
MX and thus, mitochondrial DNA damage mediates the apoptotic cell death.  
 Mitochondrial DNA damage – and more specifically AP site formation in 
mitochondrial DNA – is characterized in fludarabine alone or fludarabine plus MX 
treatments. Mitochondrial DNA damage is then correlated with known markers of 
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programmed cell death to demonstrate that fludarabine targets the mitochondria and 
promotes release of cytochrome c and other pro-apoptotic proteins, eventually triggering 
caspase activation and the apoptotic process.  
 Valuable information suggesting a mitochondrial mediated apoptotic death after 
fludarabine and MX treatments is obtained, which could place the mitochondrial 
apoptotic pathway in the focus of future studies on the mechanisms of cell killing by 
fludarabine.   
 
4. To examine whether the combination of fludarabine and the BER inhibitor MX 
can represent a new therapeutic strategy for improving the treatment of chronic 
lymphocytic leukemia (CLL)  
 To confirm the hypothesis that combination treatment of fludarabine and MX has 
greater antineoplastic activity when compared with single agents, modulation of 
fludarabine activity by manipulating BER via MX is analyzed in a series of experiments 
employing CLL patient samples. The MX enhancement of activity of fludarabine is 
confirmed, since CLL cells are significantly more sensitive to the fludarabine in 
combination with MX as assayed by cytotoxicity, apoptosis, and levels of DNA damage.  
 These studies show that through manipulation of the BER pathway, an increase in 
response to fludarabine is achieved in CLL lymphocytes. The combination of fludarabine 
plus MX represents a potential new clinical targeted therapy with lower toxicity to 
normal cells. 
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CHAPTER III  
UDG IS A MAJOR DNA GLYCOSYLASE HAVING ACTIVITY ON 
F:T MISPAIRS: IDENTIFYING A NEW TARGET FOR 
FLUDARABINE 
 
 
 
Abstract  
 Fludarabine primary cytotoxic mechanism of action is mediated by the 
incorporation of F-ara-ATP into DNA leading to subsequent inhibition of DNA 
replication. We hypothesized that the incorporation of F-ara-adenosine as an abnormal 
base initiates the sequential repair cascade to produce AP sites through a DNA 
glycosylase, the first step in BER. However, the molecular mechanism of BER to 
process incorporated fludarabine is not known. In this in vitro study, using 
oligonucleotide substrates containing F-ara-adenosine: thymidine mispairs (F:T), we 
examined the cleavage activity of five purified DNA glycosylases. Our results showed 
that only UDG can recognize F:T mispairs and excise 2-fluoroadenine from DNA, 
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displaying a time- and concentration-dependent cleavage. Analysis of products of the 
enzymatic reaction, as performed by LC-ESI-mass spectrometry revealed 2-
fluoroadenine as the cleaved product after reaction. Similarly, cleaved products of the 
UDG enzymatic reaction were seen when the F-ara-A oligonucleotide substrate was 
incubated with cell extracts from HL60 or Jurkat cells, as observed by electrophoresis 
on denaturing acrylamide gels. To evaluate the relative substrate specificity of UDG, 
the kinetics of excision of F-ara-A were compared with uracil in a double-stranded 
oligonucleotide. The results show that, although the specificity of UDG for F-ara-A 
residues is ~20-fold lower compared to uracil, F-ara-A is also a substrate for UDG. 
Moreover, the cleavage activity of UDG in purified form or in cell extracts can be 
abolished or reduced by UDG specific antibody or uracil glycosylase inhibitor, 
respectively. Our results indicate that BER can process incorporated fludarabine 
through the recognition and removal of 2-fluoroadenine in DNA by UDG.  
 
3.1.       Introduction 
 Most chemotherapeutic agents currently used in the treatment of cancer, directly 
or indirectly damage DNA causing direct base damage, misincorporation of analogs, 
formation of single or double-strand breaks or interfering with DNA-interacting proteins. 
The cellular response to these lesions is orchestrated in such way that the detection of the 
damage leads to either repair or induction of cell death (1). The repair activity of the cell 
plays an important role in cell sensitivity to anticancer agents (2,3). Thus, understanding 
the repair machinery has provided the rationale for the development of new therapeutic 
strategies to optimize the current ones.  Among all the repair mechanisms that cells have 
58 
developed, the most important one in removing non-bulky damaged nucleotides is base 
excision repair pathway (BER) (4).  
 The BER pathway involves a series of sequential steps. These steps are: (1) 
cleavage of the N-glycosidic bond by a DNA glycosylase resulting in the formation of 
abasic site (AP site); (2) cleavage of the DNA backbone at the abasic site by apurinic/ 
apyrimidinic (AP) endonuclease; (3) polymerase insertion of a templated nucleotide at 
the position of the abasic sites by DNA polymerase; (4) ligation of the nicked DNA by 
DNA ligase (Figure 3-1.) (5-9) DNA glycosylases family, the enzymes that catalyze the 
first step in BER has been extensively studied. Cells have many different DNA 
glycosylases with different but sometimes overlapping specificities. Human cells at 
present, have eleven distinct DNA glycosylases (UDG, SMUG1, TDG, MBD4, OGG1, 
MYH, NTH1, MPG, NEL1, NEL2 (10,11). Two mechanistic classes of DNA glycosylase 
are recognized: mono-functional (glycosylase activity only) such as UDG and bi-
functional (glycosylase and β-lyase activity) such as OGG1 (12,13).  
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Figure 3-1 
Base excision repair pathway 
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 One structurally well-characterized DNA glycosylase and a prototype for other 
DNA glycosylases that used base flipping mechanism is uracil DNA glycosylase (UDG). 
The primary function of UDG is to remove mainly uracil from U/G mispairs. Other 
substrates for this enzyme have been identified: 5-fluorouracil, isodialuric acid, 5-
hydroxyluracil and alloxan (14-17).  There are two isoforms of this enzyme, a nuclear 
form (UNG2, 313 amino acids) and a mitochondrial form (UNG1, 304 amino acids), 
generated from UNG gene by alternative splicing and alternative transcription start point 
(18). The two isoforms have identical catalytic domains.  UDG crystal structure revealed  
that the enzyme has a single α/β domain containing eight α-helices and a central four-
stranded parallel and twisted β-sheet (Figure 3-2. A) (19,20). The catalytic mechanism of 
action has been elucidated: DNA binds along a positively charged groove in the enzyme, 
but the tight-fitting uracil-binding pocket located at the base of this groove is too deep 
and narrow to allow binding of DNA-uracil unless it is ‘flipped out’ of DNA helix. While 
the enzyme scans the minor-groove, it “pushes” the dUMP residue from the dsDNA base 
stack via the major groove. This is associated with a compression of the DNA backbone 
flanking the uracil and specific recognition of the 5’phosphate, deoxyribose and uracil by 
UDG active-site residue which stabilizes the extra helical nucleotide confirmation. It 
promotes condensation of the surrounding catalytic residue to form a productive complex 
specific for uracil cleavage. In the UDG-DNA complex, both uracil and the deoxyribose 
phosphate are rotated by nearly 180 ° from their normal positions. The mechanism is 
described as nucleotide flipping (Figure 3-2. B) (21).  
61 
  
 
 
 
 
 
Figure 3-2 
UDG enzymatic mechanism [19,20,21] 
 A. UDG-DNA complex. B Backbone compression forced by three Ser–Pro-rich loops. 
The loops of the Ser–Pro pinch (green) compress the uracil-containing DNA strand at the 
phosphates 5' and 3' of the uracil nucleotide in the directions indicated by the arrows. C, 
The UDG Ser–Pro pinch for initial damage detection. The initial UDG–DNA complex is 
recreated by superimposing straight B-DNA (white) onto the kinked DNA seen in the co-
crystal structures (orange), and the structure of uncomplexed wtUDG (stippled magenta 
ribbons) onto the DNA-bound enzyme.  
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 Nucleotide analogs are a class of therapeutic agents that target DNA. Fludarabine, 
an adenosine analog, is used for the treatment of hematological malignancies (22). Upon 
being metabolized to its active triphosphate form, fludarabine is incorporated into DNA 
(23). Among other molecular targets such as DNA polymerase and ribonucleotide 
reductase (24-27), its incorporation may lead to activation of BER pathway. The 
molecular mechanism of BER recognition and repair of the incorporated fludarabine has 
not yet been elucidated. 
 
 3.1.1.      Hypothesis and Rationale 
Research focus: To demonstrate that BER enzymes are capable to recognize and 
initiate removal of fludarabine incorporated into DNA. 
Given that the fludarabine mechanism of action is mediated by the incorporation 
into DNA and the structural characteristics between fludarabine and adenosine (the 
normal nucleotide) are similar but still different , we hypothesized that at least one of the 
members of DNA glycosylase family, as part of BER pathway, can recognize and excise 
incorporated fludarabine.  
 We examined in vitro the enzymatic requirements for removal of incorporated 
fludarabine. Identifying the glycosylase potentially implicated in fludarabine recognition 
is important for proving the possibility that BER process is involved in processing of 
fludarabine induced-damage. It also set the stage for future, combinatory regimens.  
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     3.2.       Materials and Methods 
         3.2.1.      Cells and reagents  
 Human tumor cell lines, Jurkat (lymphoblastic), HL60 (myelocitic leukemic), 
U937 (myelononocytic), were obtained from the American Type Culture Collection 
(Rockville, MD) and cultured in proper mediums. Methoxyamine (MX) and 2-
fluoroadenine were purchased from Sigma Chemical Co (St. Louis, MO).  
 
         3.2.2.     Oligonucleotides and enzymes 
The fluorescent HEX labeled 17-mer oligonucleotide 5’-[HEX]GTAAAACGAC 
GGCCAGT-3’, the 21-mer 5’-ATTCGAGCTCGGTACCCGGGG-3’, the Cy5-labeled 40 
mer oligonucleotide, 5’-[Cy5]CCCCGGGTACCGAGCTCGAATTCACTGGCCGTCGT 
TTTAC-3’ were purchased from Operon Biotechnologies (Huntsville, Alabama).  
Complementary single-stranded oligonucleotides for U:G,  U:T and G:T mispairs were 
purchased from the same company:  
5’[HEX]GTAAAACGACGGCCAGTGUATTCGAGCTCGGTACCCGGGG-3’;  
5’-[Cy5]CCCCGGGTACCGAGCTCGAATGCACTGGC CGTCGTTTTAC-3’ for U:G;  
5’-[HEX]GTAAAACGACGGCCAGTGUATTCGAGCTCGGTACCCGGGG-3’;  
5’-[Cy5]CCCCGGGTACCGAGCTCGAATTCACTGGCCGTCGTTTTAC-3’ for U:T 
and 5’-[HEX]GTAAAACGACGGCCAGTGGATTCGAGCTCGGTACCCGGGG-3’, 
5’-[Cy5]CCCCGGGTACCGAGCTCGAATTCACTGGCCGTCGTTTTAC-3’ for G:T 
mispairs. The duplex oligonucleotides were made by annealing the two complementary 
strands in a reaction buffer containing 10 mM Tris-HCl, 50 mM KCl, 1 mm EDTA, by 
heating at 95 ºC for 5 min and  slowly cool it down at room temperature for 1 hour. 
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The T4 polynucleotide kinase and T4 ligase were purchased from Invitrogen (Carlband, 
CA). Human DNA polymerase β, E. Coli Uracil DNA glycosylase (UDG), mouse 3-
methyladenine DNA glycosylase (Aag), human 8-oxoGuanine DNA glycosylase 
(OGG1), E. Coli Mut Y DNA glycosylase (Mut Y), Thymidine DNA glycosylase (TDG) 
and human AP endonuclease were purchased from Trevigen (Gaithersburg, MD). 
 
         3.2.3.      Preparation of oligonucleotide substrates containing fludarabine 
 The procedure to construct oligonucleotide substrate containing an insertion of 
F-ara-A was performed as described by Yang et al (8) with modifications. A fluorescent 
HEX-labeled oligonucleotide, 5’-[HEX]GTAAAACGACGGCCAGT-3’ (17-mer) and 
an oligonucleotide of 5’-ATTCGAGCTCGGTACCCGGGG-3’ (21-mer) were annealed 
to a  complementary Cy5-labeled oligonucleotide (Operon Biotechnologies, Huntsville, 
Alabama),  
5’-[Cy5]CCCCGGGTACCGAGCTCGAATTCACTGGCCGTCGTTTTAC-3’(40-
mer).  
The double stranded oligonucleotides with a gap of two nucleotides at position 18 and 
19 were generated: 
5’ [HEX] GTAAAACGACGGCCAGT--ATTCGAGCTCGGTACCCGGGG  
3’ CATTTTGCTGCCGGTCACTTAAGCTCGAGCCATGGGCCCC [Cy5]    
The oligonucleotides were incubated with dGTP and DNA polymerase β, and either 
dATP or F-ara-ATP (Trevigen, Gaithersburg, MD) for 1 hr at 37 °C. After precipitation, 
the reactants were then incubated with T4 DNA ligase (Invitrogen, Carlband, CA) in a 
reaction buffer containing 50 mM Tris-HCl, pH 7.6, 10 mM MgCl2, 1 mM ATP, 1mM 
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DTT at 14 ºC for 18 hrs, producing a 40-mer oligonucleotide substrate containing either 
a normal adenine (A) or a fludarabine (B) at position 19: 
A. 5’ [HEX]GTAAAACGACGGCCAGTGAATTCGAGCTCGGTACCCGGGG  
 3’CATTTTGCTGCCGGTCACTTAAGCTCGAGCCATGGGCCCC[Cy5] 
B. 5’ [HEX]GTAAAACGACGGCCAGTGFATTCGAGCTCGGTACCCGGGG  
 3’ CATTTTGCTGCCGGTCACTTAAGCTCGAGCCATGGGCCCC[Cy5] 
Given that uracil base in DNA in vitro efficiently activates UDG excision-activity (32), 
the oligonucleotide substrates containing either uracil to thymine (U:T) or uracil to 
guanine (U:G) base pair at position 19 were constructed as well. These oligonuleotides 
were used as the control substrates to standardize UDG activity and specificity in vitro 
assay.    
 
         3.2.4.      DNA glycosylase/APE assay  
 The assay mixture for DNA glycosylase activity contained various Units (from 0-
20 Units) of purified enzymes and 4 pmol of the fluorescent labeled oligonucleotide 
duplex in 20 µl reaction buffer containing 1 mM EDTA, 1 mM dithiothreitol (DTT), and 
20 mM Tris-HCl (pH 8.0). DNA glycosylase reaction was stopped at 95°C for 5 min after 
excising 2’-fluoroadenine (F-Ade) from oligonucleotide, resultant abasic sites were 
incised by 1 Unit of APE1 treatment at 37 °C for 30 min. Reaction products were resolved 
by electrophoresis through 20 % denaturing polyacrylamide gels (7 M urea, 1x Tris-
borate-EDTA) and visualized by using a Typhoon 9200 fluorescent Imager (Amersham 
BioScience, Piscarawat, NJ). Fluorescent density was quantified using ImageQuant 
software.  
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          3.2.5.     Enzyme kinetic assays 
 To calculate enzyme kinetics parameters UDG was incubated with substrates 
(F:T, U:G and U:T) concentrations ranging from 10 to 600 nM, in the presence of APE1 
(1unit) for 30 min at 37 °C, in a volume of 100 μL. Kinetics parameters were determined 
using Michaelis-Menten fit and Lineweaver –Burk plots based on the levels of products 
produced by the reaction of oligonucleotide with UDG/APE1.  
 
        3.2.6.    Detection and quantification of 2-fluoroadenine using LC-ESI mass    
spectrometer 
 The 2-fluoroadenine standard solutions were prepared by serial dilution of 2-
fluoroadenine stock solution (1 mg 2-fluoroadenine per mL of 1 M HCl) in the enzyme 
reaction buffer (containing 29 mM Tris-HCl, 1.8 mM EDTA, 1.1 mM DTT, 42 mM 
NaCl, 3.3 mM KCl, 0.013 mg/mL BSA, and 3.3% glycerol, at pH 8.0).  The mobile 
phase was an aqueous solution 20% methanol and 0.1% formic acid. UDG glycosylase 
reaction product sample (obtained as describe above, by incubating B oligonucleotide 
substrate with purified UDG) and 2-fluoroadenine standards were pretreated by solid-
phase extraction using Waters Oasis® HLB cartridges (3 cc).  Prior to the sample loading, 
the cartridge was equilibrated with 3.0 mL of methanol, followed by 3.0 mL of 0.1 M 
phosphate buffer (pH 8.0). 0.6 mL of sample or standard was diluted with equal volume 
of 0.1 M phosphate buffer (pH 8.0) and loaded to the cartridge. The cartridge was washed 
with 4.0 mL of deionized water and the retained 2-fluoroadenine was eluted with 10% 
formic acid in methanol. The eluent was evaporated to dryness in a ThermoSavant DNA 
120 SpeedVac®.  Both the sample and the standards were six times concentrated by 
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reconstitution in 100 μL deionized water. 
An AgilentTM 1100 series HPLC system and a BrukerTM esquire HCT® ESI-ion-trap mass 
spectrometer were used for this work.  During an analysis, 20-μL sample was injected 
into the system.  The analytical separation was carried out on a Waters YMC-AQ® 
Column (2.0×50 mm, 5 μm) by isocratic elution with the mobile phase at a flow rate of 
0.1 mL/min. The mass spectrometer was operated under the following conditions: 
positive ionization mode; scan range,  m/z = 140-158; scan speed, 8,100 m/z s-1; 
nebulizer flow, 18.0 psi; drying gas flow, 5.0 L/min; drying temperature, 350oC; 
capillary, 4.0 kV; skimmer, 40.0 V; ion charge control (ICC) target, 6,000; maximum 
accumulation time, 100.00 ms; spectra averages, 10; rolling averages, 1.  The protonated 
2-fluoroadenine ion at m/z of 154 was used for the detection of 2-fluoroadenine. 
 
          3.2.7.    AP site assay  
The AP sites were measured using ARP (aldehyde reactive probe) reagent. The 
assay was performed as previously described with minor modifications (28-30). DNA (10 
μg) was incubated with 15 µl of 1 mM ARP (Dojindo Laboratories, Kumamoto, Japan) in 
150 µl PBS solution at 37 ºC for 15 min. DNA was then precipitated with 400 µl ice-cold 
ethanol (100%) at -20 ºC for 20 min and washed with 70% ethanol. DNA was dried at 
room temperature for 30 min and then resuspended in TE buffer to achieve a final 
concentration of 0.3 μg/100 µl. The ARP-labeled DNA was then heat-denatured at 100 ºC 
for 5 min, quickly chilled on ice and mixed with an equal amount of 2 M ammonium 
acetate. The DNA was then immobilized on BA-S 85 nitrocellulose membrane 
(Schleicher and Schuell, Dassel, Germany) using a minifold II vacuum filter device 
69 
(Schleicher and Schuell, Dassel, Germany). The membrane was baked at 80 ºC for 1 hr 
and incubated with 0.25% BSA/PBS containing streptavidin-conjugated horseradish 
peroxidase (BioGenex, SanRamon, CA) at room temperature for 40 min with gentle 
shaking. ARP-labeled AP sites were visualized by chemiluminescence (Amersham Corp, 
Piscataway, NJ) followed by quantitative densitometry using NIH ImageJ software.     
 
 3.3.    Results 
         3.3.1.      UDG is a DNA glycosylase having activity on F:T mispairs 
 In order to examine whether incorporation of fludarabine residue into DNA can be 
recognized and removed by BER mechanism, we constructed oligonucleotide substrates 
containing a F-ara-A:T base pair (Figure 3-3. A) and examined the activity of five 
purified DNA glycosylases, including UDG, AAG, TDG, OGG and Mut Y, excising F-
ara-A from oligonucleotide substrates (Figure 3-3.B), which is the first step of BER 
pathway. Results revealed that among these glycosylases, only UDG displayed the 
glycosylase activity to excise 2-fluoroadenine (F-Ade), producing a small fragment (∼18 
mer) after incubation with APE1 to incise the DNA backbone. No cleavage was seen as 
expected, when UDG was incubated with oligonucleotide containing a normal base-pair 
of A to T at position 19. To further confirm the specific role of UDG in recognition and 
removal of F-Ade, several experiments were performed. First, dose and time dependent 
assessment of UDG activity excising F-Ade from oligonucleotide duplex were examined 
and showed that the increased levels of cleaved fragments were proportionally correlated 
with both the concentrations of UDG and the duration of enzymatic reaction (Figure 3-
3.C). Second, to clarify that UDG excised F-Ade as an abnormal base and this excision 
70 
was not due to the molecules of arabinose, an ara-Adenine-ATP was inserted into 
oligonucleotide at position 19 instead of F-ara-A, and then UDG cleavage activity was 
examined with this substrate. Results clearly showed that UDG had no activity to remove 
ara-Adenine, leaving entire 40-mer oligonucleotide substrates (Figure 3-3.C). The results 
indicated that the molecule of arabinose sugar could not stimulate the UDG excision 
activity. Third, to verify that UDG removed base was 2-fluoroadenine (F-Ade), mass 
spectro-analysis for F-Ade released from F:T oligonucleotide substrates after UDG 
reaction was developed. After the reaction of UDG with F:T oligonucleotide substrates, 
reaction products were collected and extracted with Waters Oasis® HLB solid-phase 
extraction cartridge (3 ml) and concentrated for 6 times. F-Ade standards were prepared 
by spiking F-Ade in the reaction buffer, and extracted and concentrated with the same 
procedures used to prepare samples of UDG reaction. Analytical separation was carried 
out on Waters YMC-AQ® Column (2.0×50 mm, 5 μm particle size with 120 Ǻ pore size) 
by isocratic elution with the mobile phase (i.e., 20 % methanol with 0.1 % formic acid) at 
a flow rate of 0.1 ml/min. As shown in Figure 3-2. D, F-Ade in UDG reaction buffer was 
detected by ESI-IT mass spectrometer (c), which was confirmed by standards of 2-
fluoroadenine (a, b). Samples containing F:T substrate but without UDG showed no 
detectable F-Ade (d). 
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Figure 3-3 
Double-stranded DNA oligonucleotide containing  
F:T mispairs is a substrate for UDG 
A, Schematic diagram represents the preparation of oligonucleotide substrates containing 
F:T mispairs and the products of reaction of DNA glycosylase/APE with the 
oligonucleotide substrates. B, Oligonucleotide duplex containing F-ara A (F:T) was 
incubated with 5 DNA glycosylases ( UDG, OGG, TDG, AAG and MutY) at 37 ºC for 1 
hr and followed by incubation with APE1 at 37 ºC for 30 min. Reaction products were 
resolved by electrophoresis through denaturing 20 % polyacrylamine gels. C, UDG has 
the activity excising F-Ade in a dose and time dependent fashion, but it has no activity to 
cleave the substrates containing either A:T or ara-A:T. D, Identification of reaction 
product of UDG on F:T substrate by HPLC-ESI-mass spectrometer. Schematic diagram 
of the enzymatic reaction with the hydrolysis of the N-glycosydic bound between 
arabinose and 2-fluoroadenine residue. UDG reaction samples were analyzed after 
incubation of F:T substrate with UDG for 3 hrs.  
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     3.3.2.  Enzymatic kinetics of UDG activity excising 2-fluoroadenine from 
 double stranded oligonucleotide 
 To characterize UDG activity excising F-Ade, kinetic analysis was performed 
using a 40-base oligonucleotide duplex containing either F:T or U:G, or U:T base pairs. 
In this assay U:G oligonucleotide as the specific substrate of UDG was used to 
standardize enzymatic activity. U:T substrates were used as controls to examine whether 
T in an opposite strand affects UDG activity in comparison with U:G. Given that the 
removal of the target base from 40-mer double-stranded oligonucleotide generated an AP 
site that was incised by APE1, resulting in a fragment (∼18 mer), the UDG activity was 
measured based on the levels of cleaved products (Figure 3-3.C). As shown in Figure 3-
4.A, when 5 units of purified UDG and 4 pmol of either F:T or U:G substrates were used 
for reaction, enzyme-catalyzed reactions were saturable, their rate of catalysis does not 
show a linear response to increasing substrate. UDG produced products at a linear initial 
rate followed by a slower rate at later time points. In comparison with uracil substrates, 
the rate of UDG excising F-Ade was much slower, Vmax was 0.51 nM/min compared to 
3.62 and 6.31 nM/min for U:G and U:T substrates respectively (Table 3-I). The products 
of F-Ade were much lower than uracil excised by UDG, even after increased 
concentrations of UDG (up to 20 units, Figure 3-4. B) and prolonged reaction time (60 
min, Figure 3-4. C). The kinetic parameters of excision of uracil or F-Ade from 
oligonucleotide substrates using purified UDG were shown in Table 3-I. It was noted that 
the rate of turnover (Kcat) of UDG against U:G or U:T was high, about 7-12-fold faster 
than that against F:T. The specificity constant (Kcat/Km) of UDG for F-Ade was 19-fold 
lower than for uracil excised from either U:T or U:G oligonucleotide substrates. Data 
indicate that F-ara-A is the substrate of UDG, but with low enzymatic specificity.
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Figure 3-4 
Enzymatic kinetics of UDG activity to excise 2-fluororadenine or uracil from 
oligonucleotides containing F:T, U:T and U:G mispairs 
 A, The UDG catalyzed reaction: relation between the concentration of substrate and rate. 
UDG was incubated with increasing concentrations of F:T or U:G substrate (10-600 nM) 
for 30 min at 37 ºC in the presence of APE1 (1U). The cleavage products were analyzed 
by 20 % denaturing polyacrylamide gel electrophoresis. The velocities of the reactions 
were plotted against the substrates concentrations using Michaelis-Menten fit. Each point 
represents the mean value from at least three independent experiments. B, Left panel: 
Enzymatic activity of UDG was measured as a function of enzyme concentration (0-20 
units) and the substrates (4 pmols) at 37 ºC for 1 hr. Right panel:  Enzymatic activity of 
UDG (5 units) was measured as a function of reaction time (0-60 min). Results are 
representative of at least three independent experiments. 
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Table 3-I: The kinetic parameters of uracil or F-Ade excision from oligonucleotide 
substrates using purified UDG  
 
 
340 ± 89
221 ± 19
122 ± 43
Km
(nM)
5.70 ± 0.291.260 ± 0.076.314 ± 0.50U:T
5.92 ± 1.230.723 ± 0.113.617 ± 0.11U:G
0.30 ± 0.010.102 ± 0.020.514 ± 0.03F:T
Kcat/Km 
(x10-3 min-1 nM-1)
Kcat
(min-1)
Vmax
(nM/min)
substrate
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3.3.3. Characterization of UDG glycosylase activity in cell extracts for 
excising F:T mismatch 
 We next examined the ability of DNA glycosylases in cell to recognize and excise 
F-ara-A from the oligonucleotide substrates. As shown in Figure 3-5. A and B, 
oligonucleotide duplex containing F:T base pair was fragmented and the cleaved products 
were increased proportionally with the concentrations of cell extracts from HL60 
leukemia or Jurkat lymphoma cells (Figure 3-5. A, B). To further clarify the UDG 
cleavage activity of F-Ade in cells, the Uracil Glycosylase Inhibitor (Ugi, NewEngland 
Biolabs, Ipswich, MA) was used to inhibit UDG from cell extract. Ugi has been shown to 
bind and form a tight complex with UDG (E. Coli or human), thus inhibiting UDG 
activity (31,32). 
As illustrated in Figure 3-5. C, the glycosylase activity of UDG both purified and 
cellular enzyme on F-Ade from oligonucleotide substrates was completely inhibited after 
pre-incubated with Ugi. Similarly, the UDG antibody was added in cell extracts from 
HL60 cells prior to the reaction with substrates in order to specifically reduce UDG 
activity, the reduction of UDG activity was seen by the decrease in cleaved products 
which was correlated to the increase in the concentration of UDG antibodies. The UDG 
antibody at concentrations of 10 - 20 µg/ml resulted in 80-90 % reduction of the cleaved 
fragments compared to that produced by cell extracts containing entire UDG activity 
(Figure 3-5. D). In contrast, cell extracts efficiently and completely excised uracil from 
inserted strand of oligonucleotide (U:T), even at low protein concentrations (2.5 μg), 
showing the cleaved fragments with strong density of green fluorescence and a intact 
complemented oligonucleotide (40-mer) labeled with Cy5 (red). Reduced activity of 
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UDG for excision of uracil was only seen when UDG-antibody was used up to high 
concentrations (20 μg/ml). These results indicate that in human cells, uracil is the 
common substrate for UDG. UDG antibody did not completely abolish UDG activity in 
cell extracts, suggesting that in cell UDG is not a sole glycosylase to remove uracil from 
DNA. 
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Figure 3-5 
Cleavage of oligonucleotide containing F:T by UDG 
in cell extracts from HL60 and Jurkat cells 
Oligonucleotide duplex containing F:T or U:T base-pair was incubated with various 
concentrations of cell extracts (2.5- 40 μg) at 37 ºC for 30 min. The products of reaction 
were analyzed by electrophoresis on 20 % denaturating polyacrylamide gel. A, HL-60 
cells B, Jurkat cell C, UDG activity in cell extracts was inhibited by Ugi (Ugi was pre-
incubated with cell extracts at 37 ºC for 30 min). D, UDG activity in cell extracts from 
HL-60 cells was reduced by UDG specific antibody. Results are representative of at least 
three independent experiments.  
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3.3.4.  The formation of abasic sites of arabinosyl nucleotides (ara-AP site) 
 after UDG cleavage of  2-fluoroadenine 
 Studies in vitro and ex vivo using oligonucleotide demonstrated that F-ara-A 
residues in DNA were recognized and removed by UDG. However, it is not clear whether 
the BER process of fludarabine occurs in cells. Thus, to detect the formation of ara-AP 
sites is like confirming the initial step of BER in process of incorporated fludarabine in 
DNA. We have measured AP sites using an aldehyde reactive probe reagent (ARP). ARP 
has been demonstrated to bind to an aldehyde group in an AP site of the natural 
deoxyribosyl sugar. However, we do not know whether the AP site of an arabinosyl sugar 
can be detected by ARP. Therefore, in this study, ARP was the first time used to measure 
ara-AP sites induced by fludarabine. A 40 mer oligonucleotide containing either F:T 
mispair, A:T normal base pairing or U:T mispairs were reacted with purified UDG for 30 
min, at 37 °C. The reaction was stopped and the DNA was extracted using ethanol. The 
extract DNA duplex was labeled with ARP and the ara-AP sites were quantitated. As 
shown in the Figure 3-6. when the normal, A:T oligonucleotide  was reacted with UDG, 
no AP sites were detected due to lack of enzymatic cleavage by UDG. In contrast, when 
40 mer double stranded oligo containing F:T mispairs was incubated with UDG and 
labeled, we detected AP sites. The levels of AP sites formed were lower that those 
obtained using U:T substrate, as the control substrate.  
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Figure 3-6 
Ara-AP sites formed by UDG using substrate containing F:T mispairs 
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      3.4.     Discussion 
 In the present chapter we have demonstrated that: (i) among the five purified 
DNA glycosylases tested, UDG was identified as the enzyme responsible for recognition 
and removal of fludarabine incorporated in a synthesized 40-mer double stranded 
oligonucleotide, (ii) kinetic studies have shown that F-ara-A is a substrate for UDG with 
a lower specificity of the enzyme for this substrate and (iii) UDG was also responsible for 
cleavage of fludarabine when whole tumor cell extracts were used.  
 DNA glycosylases remove a large number of cytotoxic bases from DNA. Some of 
the enzymes have narrow specificities, whereas most can remove a large variety of 
structural different bases. Noteworthy, some glycosylases have overlapping substrate 
specificities which serve as a backup function (11). Using oligonucleotide substrates 
containing F-ara-A residues, we demonstrated that in vitro and ex vivo purified UDG 
excised incorporated F-ara-A from DNA, showing a direct relationship between the UDG 
activity and the levels of excision of incorporated F-ara-A. By determining the enzyme 
kinetic parameters, we confirmed that UDG is active against F-ara-A, but with a 19-folds 
lower catalytic efficiency when compared with the UDG specific substrate, uracil. 
Furthermore, using human cell extracts that were either depleted of the enzyme, either 
with UDG activity altered with a specific inhibitor (31,32), we confirmed that the 
cleavage of the F-ara-A is initiated by UDG.  
 Furthermore, the available evidence (J. Biol. Chem. 265: 16617-16625, 1990) 
demonstrated that following its incorporation into the 3' terminus, the fludarabine 
nucleotide is a poor substrate for addition of a subsequent nucleotide. Thus, evaluating 
the activity of UDG against a substrate that contains the analogues at the 3’ position 
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would model the other portion of the lesions that occur in whole cells. Even though this 
question was not answered in vitro, our in vivo experimental approach and results 
presented in Chapter 4 confirmed the role of UDG in removal of incorporated 
fludarabine, regardless of possible locations of incorporated fludarabine.  
 Previous research has characterized the details of the chemical mechanism by 
which UDG catalysis the removal of uracil residues from the DNA strand. The catalytic 
unit of the enzyme gains access to the glycosidic bond by flipping the target nucleotide 
out of the DNA helix. The very specific interaction between the active site of the enzyme 
and the target lesion weaken the glycosidic bond, allowing rapid hydrolysis (11,20). One 
could assume that UDG catalysis fludarabine-base removal by a similar mechanism.  
 In the case of fludarabine molecule both the sugar moiety and the base are 
modified when compared with common nucleotide structure. The sugar moiety of 
fludarabine is arabinose, while the base part contains a fluorine substitute in the second 
position of the adenine ring. Considering these differences, we decided to test the 
eventual involvement of the sugar. Thus, we synthesized a 40 mer oligonucleotide 
(AraA:T) containing the sugar moiety of fludarabine attached to the adenine, the common 
unmodified base (of adenosine). Studies using AraA:T substrate and purified UDG  have 
demonstrated that the sugar moiety of the fludarabine molecule does not participate in  
UDG catalytic mechanism.  
 The base contained in fludarabine molecule is not the typical pyrimidinic 
substrate for UDG. Still, we believe that the presence of fluorine substitute at the second 
position of the adenine ring is a key structural feature for UDG activity on fludarabine.  
Previous studies have shown that indeed, other molecules containing fluorine substitutes 
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interact with UDG. For instance, 5-flurouridine is as substrate for UDG while 
gemcitabine (the hydrogens on the 2' carbons of deoxycytidine are substituted with 
fluorines) is able to inhibit the enzyme (33, 34). 
 Future studies involving crystal structure of human UDG bound to DNA 
containing F-ara-A will be focus on elucidating how UDG recognizes and removes 
fludarabine base and establish the role of the fluorine substitute in the biochemical 
mechanism of the enzymatic reaction. Also, considering that we did not test all eleven 
DNA N-glycosylases identified in mammalian cells, we could not rule out the possibility 
that other glycosylases may be capable to excise F-ara-A from DNA in cells. 
 In summary, our in vitro tests suggest that UDG is the major DNA glycosylase 
involved in excision of incorporated F-ara-A.  In Chapter 4 of this material we present 
our in vivo experimental approach and results underlying the importance of UDG in 
response to fludarabine treatments.    
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CHAPTER IV  
TARGETING BASE EXCISION REPAIR BY METHOXYAMINE 
ENHANCES FLUDARABINE INDUCED CELL DEATH 
 
 
 
Abstract 
 Fludarabine is a widely used anticancer drug. The inhibition of DNA replication 
via incorporation of F-ara-ATP into DNA and subsequent chain termination is thought to 
be its primary cytotoxic action. Here, AP (apurinic/apyrimidinic) site as a new target of 
fludarabine was identified and a novel therapeutic strategy combining fludarabine with 
methoxyamine (MX), an agent that blocks BER through its binding to AP site, was 
examined. This strategy rests on the hypothesis that the incorporation of fludarabine into 
DNA activates BER pathway to process F-ara-A as an abnormal base and to generate an 
ara-AP site, which is the target for MX. In cells, we found that formation of ara-AP sites 
was increased proportionally with concentrations and exposure time of fludarabine and 
that MX efficiently bound these ara-AP sites to form stable DNA lesions that have the 
92 
potential to interrupt BER mechanism, leading to cell death. Moreover, MX markedly 
enhanced fludarabine induced cytotoxic effect in tumor cells and therapeutic effect in 
human tumor xenografts. Taken together, our findings indicate for the first time that in 
cell BER can process incorporated fludarabine. They also provide insights into possible 
leads to new and promising therapeutic strategies to enhance the antineoplastic activity of 
fludarabine. 
 
4.1.      Introduction 
Fludarabine (2-fluoroadenine 9-β-D-arabinofuranoside-monophosphate), a purine 
nucleoside analogue, is effective for the treatment of indolent lymphoproliferative 
disorders such as acute myelogenous leukemia, acute and chronic lymphocytic leukemia 
and low-grade non-Hodgkin’s lymphoma (1-4).  
In cell, fludarabine (F-ara-A) is rapidly converted to the triphosphate species (F-
ara-ATP), which is the active form to incorporate into DNA and RNA strands (5). The 
incorporated F-ara-A serves as a poor substrate for DNA replication enzymes, leading to 
the inhibition of DNA replication. Several related molecular targets have been identified, 
including ribonucleotide reductase, DNA polymerases α, β, γ, and ε, DNA primase, and 
DNA ligase (6-8). Therefore, the primary action of fludarabine is thought to affect 
replicating cells (9, 10). In addition, fludarabine induced inhibition of ribonucleotide 
reductase results in depletion and imbalance of the deoxynucleotide pools required for 
DNA repair and synthesis, subsequently may favor itself and other mismatched 
nucleotides to incorporate into newly synthesized DNA strand. Collectively, stalling DNA 
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replication, chain termination and free DNA ends also trigger apoptosis, leading to cell 
death.  
Given that the primary action of fludarabine is through its incorporation into 
DNA, we hypothesize that incorporated F-ara-A seen as an abnormal base in DNA 
activates base excision repair (BER). BER is the major DNA repair pathway to process 
small base modifications generated by mis-insertions from imbalanced nucleotide pool, 
deamination of cytosine to uracil, environmental mutagens, or anticancer agents (11). 
BER pathway is prototypically initiated by a DNA glycosylase to remove a specific base 
lesion and to generate an apurinic/apyrimidinic or abasic site (AP site) (12, 13). The AP 
endonuclease (APE) is responsible for repair of the resultant AP sites by incising the 
phosphodiester backbone of damaged DNA immediately 5' to an abasic site, leading to 
the formation of a 3’-hydroxyl residue and a 5’-deoxyribose phosphate (5’-dRP). In 
mammalian cells completion of BER occurs via two pathways, short-patch (single 
nucleotide) or long-patch (2-10 nucleotides) repair, depending on the ability to remove the 
5’-dRP and to complete repair syntheses (14,15). In the short-patch pathway, DNA 
polymerase β removes the 5’-dRP residue and fills one nucleotide in the gap, which is 
then sealed by a DNA ligase III (16). In the alternative long patch BER process, the 5’-
deoxyribosephosphate flap structure is excised by flap endonuclease (FEN1), DNA repair 
synthesis and strand displacement are done by polymerase β, δ/ε (17-20). BER is the most 
efficient repair mechanism to repair a variety of base lesions. Thus, while BER protects 
cell from DNA damage, it also causes cell resistance to anticancer agents that produce 
DNA lesions repaired by BER (21). To overcome BER conferred drug resistance, 
methoxyamine (MX) has been studied (22, 23) and developed as an active inhibitor of 
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BER. The specific action of MX is to specifically react with an aldehyde group in the 
sugar moiety left at an AP site and to form a MX-bound AP-site. This structural modified 
AP site is refractory to the repair activity of APE in BER pathway, resulting in the 
persistence of the DNA lesion (17). MX has been demonstrated to enhance therapeutic 
efficacy of different alkylating therapeutic agents (24-31) and currently is being evaluated 
in clinical trials for its therapeutic value. 
 
4.1.1. Hypothesis and Rationale 
Research focus: To demonstrate BER involvement in fludarabine-induced damage 
and to investigate the effect of MX on blocking the repair process 
In this work BER response to fludarabine-induced DNA damage was determined.  
Based on the structural differences between fludarabine and adenosine (the normal 
nucleotide), we hypothesized that incorporated fludarabine in DNA triggers activation of 
BER pathway. This leads to the subsequent hypothesis that methoxyamine, a known 
inhibitor of BER, blocks fludarabine induced BER response and thus, enhances 
fludarabine cytotoxicity.  
We examined whether incorporated fludarabine is a substrate for BER and tested 
whether blockage of BER by MX can potentiate fludarabine cytotoxicity in vitro and in 
human tumor xenografts. Our results support our hypotheses and reveal the role of BER 
activity in cellular sensitivity to fludarabine. These data provide a rationale for the clinical 
development of fludarabine and MX in the treatment of hematological malignancies.  
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Figure 4-1. 
Working model: BER response to Fludarabine-induced DNA damage 
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 4.2.      Materials and Methods 
           4.2.1.    Cells and reagents  
 Human tumor cell lines, Jurkat (lymphoblastic), HL60 (myelocitic leukemic), 
U937 (myelononocytic), SW480 and RKO (colon cancer) used in these studies were 
obtained from the American Type Culture Collection (Rockville, MD) and cultured in 
proper mediums. DLD1/UDG-/- cells were kindly provided by Dr. Sanford Markowitz. 
Fludarabine was obtained from Berlex Laboratories (Richmond, CA) and freshly 
prepared with mediums (containing alkaline phosphatase) for the treatment. 
Methoxyamine (MX) was purchased from Sigma Chemical Co (St. Louis, MO). MX was 
dissolved in sterilized water (pH 7.0) and stock solution (2.5 M) was stored at -20 ºC.  
           4.2.2.    AP site assay  
 The AP sites were measured using ARP (aldehyde reactive probe) reagent that 
reacts with an aldehyde group at an AP sites and competes with MX to bind to AP sites. 
Therefore, this reagent only detects MX-free AP sites. The assay was performed as 
previously described with minor modifications (24, 32-34). Briefly, cells (2x106) were 
plated and exposed to fludarabine (0-20 µM) with or without MX (3 mM). Cells were 
collected at 24 hr after treatment and dose-dependent AP sites were measured. 
Alternatively, for the time-dependent assay, cells were exposed to 5 µM fludarabine with 
or without MX (3 mM) for a period of 72 hrs. Cells were harvested at 12, 24, 48 and 72 
hr, respectively. After extracting by phenol (Fischer Scientific, Fair Lawn, NJ) and 
chloroform (Sigma-Aldrich, St Louis, MO), DNA (10 g) was incubated with 15 µL of 1 
mM ARP (Dojindo Laboratories, Kumamoto, Japan) in 150 µL PBS solution at 37 ºC for 
15 min. DNA was then precipitated with 400 µL ice-cold ethanol (100 %) at -20 ºC, 
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overnight and washed with 70% ethanol. DNA was dried at room temperature for 30 min 
and then resuspended in TE buffer to achieve a final concentration of 0.3 g/100 µL. The 
ARP-labeled DNA was then heat-denatured at 100 ºC for 5 min, quickly chilled on ice 
and mixed with an equal amount of 2 M ammonium acetate. The DNA was then 
immobilized on BAS 85 nitrocellulose membrane (Schleicher and Schuell, Dassel, 
Germany) using a minifold II vacuum filter device (Schleicher and Schuell, Dassel, 
Germany). The membrane was baked at 80 ºC for 1 hr and incubated with 0.25 % 
BSA/PBS containing streptavidin-conjugated horseradish peroxidase (BioGenex, 
SanRamon, CA) at room temperature for 40 min with gentle shaking. The nitrocellulose 
membrane was rinsed with washing buffer containing NaCl (0.26 M), EDTA (1 mM), 
Tris-HCl (20 mM) and Tween 20 (1 %) for 1 hr at room temperature. ARP-labeled AP 
sites were visualized by chemiluminescence (Amersham Corp, Piscataway, NJ) followed 
by quantitative densitometry analysis using NIH ImageJ software.  
4.2.3. Cell Growth Assay 
 HL60 and Jurkat cells were seeded in complete growth medium in a 6-well plate 
(Falcon, Becton Dickinson) at a density of 5×10
5 
cells per well. Cells were treated with 
fludarabine or fludarabine plus MX and counted using a hemocytometer every 24 hr for 5 
days. 
4.2.4. Colony survival Assay 
 Tumor cells (2000/dish) were plated and treated with fludarabine (0-20 μM) or 
fludarabine plus MX (3 mM) for 24 hrs. After treatment the drugs were removed, fresh 
medium was added to the cells for 7 days. Survived colonies were stained with methylene 
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blue for 30 min at room temperature and the colonies containing more than 50 cells were 
counted to generate survival curves. To compare drug induced cytotoxicity DMF 
parameter was calculated. DMF is defined as the ratio of the IC50 of fludarabine alone to 
the IC50 obtained in the presence of the indicated modifier (DMF = IC50 for fludarabine 
alone / IC50 for fludarabine plus MX). DMF indicates the degree of potentiation of 
cytotoxicity by the modulator. 
 
         4.2.5.      Comet assay 
 The single cell comet electrophoresis assay was performed using Comet Assay kit 
(Trevigen, Gaithersburg, MD). Approximately 5000 (in 50 µl) cells after exposure to 
drugs were mixed with 250 µl of 1 % low melting point agarose in 1x PBS at 37 ºC.  The 
mixture (75 µl) was quickly pipetted onto a Comet slide (Trevigen, Gaithersburg, MD) 
and allowed to solidify at 4 ºC. Slides were immersed for 30 min in prechilled lysis buffer 
(2.5 mM sodium chloride, 100 mM EDTA pH 10, 10 mM Tris Base, 1 % sodium lauryl 
sarcosinate, 0.01 % Triton X-100) at 4 ºC. After lyses, slides were incubated for 20 min in 
alkali solution (0.3 M NaOH, 1 mM EDTA) at room temperature to allow unwinding of 
DNA and then subjected to both neutral and alkaline electrophoresis for the next 30 min. 
Comet in an individual cell was visualized by staining with Comet silver staining kit 
(Trevigen, Gaithersburg, MD). Fifty cells per treatment were analyzed using NIH ImageJ 
software to generate quantitative and statistical data. Cellular DNA damage was 
expressed as the tail “length” and the “tail moment” that combines a measurement of the 
length of the DNA migration and the relative DNA content therein (26, 35). 
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         4.2.6.      Western blot analysis 
 Cellular protein content was quantified spectrophotometrically using the Bio-Rad 
assay. Equal amounts of proteins (30 µg) were separated by SDS-PAGE and transferred 
to PVDF membrane (Millipore Cor., Bedford, MA). After blocking in 5 % non-fat dry 
milk in TBST for 40 min at room temperature the blots were incubated with primary 
antibody for 1 hour at room temperature. Sources of primary antibody were as follows: 
APE, FEN1, PCNA, polymerase β, TDG (Santa Cruz Biotechnology, CA), UDG, MPG, 
MBD4 (Abcam, Cambridge, MA), cleaved PARP (BD Pharmingen, San Jose, CA), 
γH2AX (Bethyl, Montgomery, Texas), α-Tubulin (Sigma-Aldrich, St Louis, MO), Ogg1 
(Novus Biological, Littleton, CO). The primary antibody solutions were prepared in 1 % 
non-fat dry milk in TBST as followed: cleaved PARP 1: 1000 v/v dilution, APE 1:2000 
v/v dilution, Fen1 1:200 v/v dilution, polymerase β 1:200 v/v dilution, UDG 1:500 v/v 
dilution, PCNA 1:200 v/v dilution, TDG 1:200 v/v dilution, MPG 1:500 v/v dilution, 
MBD4 1:500 v/v dilution, γH2AX 1:1000 v/v dilution, Ogg1 1:500 v/v dilution  and 
Tubulin 1:500 v/v dilution. Blots were incubated with HRP-conjugated secondary 
antibody at room temperature for 1 hour. The blots were visualized by ECL (Amersham 
Corp, Piscataway, NJ) according to the manufacturer instructions.  
  
        4.2.7.       RT-PCR assay 
 Total RNA was isolated from ~5 x 106 cells using RNAqueous-4PCR kit 
(Ambion, Austin, TX) according with the manufacturer’s instructions. The extracted 
RNA was quantitated by measuring absorbance at 260 nm using NanoDrop100 
spectrophotometer (Thermo Scientific, Wilmington, Delaware). Then cDNA was 
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synthesized from 5 μg of total RNA in a 20 μL reaction mixture according to the 
manufacturer’s instructions using SuperScript III first strand kit (Invitrogen, Frederick, 
Maryland) with random hexamers. The thermal profile of the reaction was set for stage 1: 
10 min at 25 ºC; stage 2: 50 min at 50 ºC and stage 3: 5 min at 85 ºC.  TaqMan MGB 
probes (FAMTM dye labeled) for nuclear UDG (NM 080911.1) and β-actin 
(NM001101.2) were used. To amplify the cDNA, 0.25 μg of the reversed transcribed 
cDNA from cells were subjected to 40 cycles of PCR using TaqMan one-step RT-PCR 
master mixture reagent kit in a 96-well optical plate. The cycling parameters in an ABI 
7500 Fast Real-Time PCR System (Applied Biosystem, Foster City, CA) were as 
follows: stage 1: 50 ºC for 2 min; stage 2: AmpliTaq activation 95 ºC for 10 min; stage 3: 
40 cycles of amplification at  95 ºC for 15 s and stage 4: 60 ºC for 1 min. The amount of 
target was calculated after normalization to the β-actin as an endogenous control. 
 
         4.2.8.      Immunofluorescence microscopy 
 Cells were grown on a 6 well plate and were treated with fludarabine and 
fludarabine plus methoxyamine for 24 and 48 hrs. At each time point, cells were washed 
with PBS and cytospin on a slide at 600 g for 8 min. Both treated and untreated cells 
were fixed in 2 % paraformaldehyde and permeabilized with 0.2 % Triton X-100. Cells 
were incubated with primary UDG antibody (Abcam, Cambridge, MA) for 1 hr at room 
temperature, followed by secondary antibody conjugated with Alexa 488 (green) 
(Molecular Probes, Carlsband, CA). Nucleus was stained using Hoersch dye, 2 mg/ml, 
for 30 min at room temperature. Images were digitally captured using an Olympus 
microscope equipped with a digital camera.  
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         4.2.9.      Xenograft tumors in nude mice 
  HL60, U937 and SW480 tumor cells (5 x 106) were injected into bilateral flanks 
of female athymic nude mice (6 weeks old). The tumors were measured with calipers and 
the tumor volume was calculated using the formula: V = L x I2 / 2, where V= tumor 
volume (mm3), L is the largest diameter and I is the smallest diameter. When the tumor 
volumes reached 100-150 mm3, mice were divided in control and treatment groups (6-9 
mice/group).  
 Nude mice carrying tumors were treated with fludarabine alone (15 mg/kg), MX 
(2 mg/kg) alone and the combination of the two agents, by daily intraperitonial injection 
(i.p.) for 5 consecutive days. Tumor measurements were taken every 2 days. Tumor 
responses were quantified by tumor growth delay. Tumor growth delays were calculated 
using the formula: T2x – C2x, where T2x= the days to double tumor in size in drug treated 
tumor, C2x= the days to double tumor in size in untreated tumor. Toxicity of the treatment 
was evaluated by measuring the body weight three times weekly from the first day of 
treatment until 2 weeks after the last treatment and also by analysis of whole blood counts 
(days 1, 5, 10 and 15 after treatment). 
 
         4.2.10.     Statistical analyses 
  All results were expressed as mean ± SE. Statistical tests were performed using 
InStat3.06 (GraphPad). P < 0.05 was considered statistically significant. 
  
4.3. Results 
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 4.3.1.     The formation of abasic sites of arabinosyl nucleotides (ara-AP site) in   
cells after exposure to fludarabine alone and in combination with MX 
 Studies in vitro and ex vivo using oligonucleotide demonstrated that F-ara-A 
residues in DNA were recognized and removed by UDG (presented in chapter 3). 
However, it is not clear whether the BER process of fludarabine occurs in cells. Thus, to 
detect the formation of ara-AP sites in cells after exposure to fludarabine is like 
confirming the initial step of BER in process of incorporated fludarabine in DNA. We 
have measured AP sites in cells induced by alkylating agents (24) using an aldehyde 
reactive probe reagent (ARP). ARP has been demonstrated to have similar chemical 
structures to MX that can specifically bind to an aldehyde group in an AP site of the 
natural deoxyribosyl sugar (23, 24). However, we do not know whether the AP site of an 
arabinosyl sugar can be detected by ARP in cells. Therefore, in this study, ARP was the 
first time used to measure ara-AP sites induced by fludarabine. Results showed that dose 
and time dependent formation of ara-AP sites were detected in three cancer cell lines, 
HL60, Jurkat and SW480 after fludarabine treatments (Figure 4-2. A & B) and that co-
treatment with MX reduced detectable ara-AP sites. This reduction of ara-AP sites is 
presumably due to the binding of MX to the aldehyde group of the ara-AP site to form a 
MX-bound AP-site (24), making the ara-AP site unavailable for ARP. Importantly, these 
results indicate that MX is capable of blocking the repair of incorporated fludarabine. The 
ara-AP site assay was also performed in DLD1/UDG+/+ and DLD1/UDG-/-cells after 
fludarabine treatments. While the formation of ara-AP sites induced by fludarabine 
displayed a dose dependent effect in UDG+/+ cells, no increased ara-AP sites were 
detected in UDG-/- cells (Figure 4-3. A) after exposure to increasing doses of fludarabine. 
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Thus, no detectable ara-AP sites in UDG-deficient cells were the results of the lack of 
UDG activity to recognize and remove incorporated F-ara-A, confirming that the activity 
of UDG plays the role in the initial repair-process of fludarabine in cells. Additionally, 
when genomic DNA extracted from these cells was incubated in vitro with purified UDG 
enzyme and then label with ARP, no significant increase in ara-AP sites formation was 
measured in UDG+/+ cells. In contrast, considerable increase in ara-AP sites was detected 
in UDG-/- (Figure 4-3. B & C). 
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Figure 4-2 
Fludarabine induces formation of ara-AP sites that are bound by MX 
 A, The dose-dependent relationship between the levels of ara-AP sites and the 
concentrations of fludarabine. The ara-AP sites in DNA were measured using ARP 
reagent after HL60, Jurkat and SW480 cells were treated with fludarabine alone (0-20 
μM) or in combination with MX (3 mM) for 24 hrs (* P<0.05 compared to fludarabine 
alone). B, The time-dependent relationship between the numbers of ara-AP sites and the 
length of time of exposure to fludarabine. The ara-AP sites were measured in Jurkat, 
HL60 and SW480 cells treated with fludarabine alone (5 μM) or fludarabine plus MX (3 
mM) for 12, 24, 48 and 72 hr  (* P<0.05 compared to fludarabine alone). Results 
represent the mean value of data from three independent experiments. 
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Figure 4-3 
Fludarabine induces formation of ara-AP sites in UDG wild-type cells but not in 
UDG-/- cells 
A, Comparison of the formation of ara-AP sites in colon cancer cells DLD1/UDG+/+ 
versus DLD1/UDG-/- cells after exposure to fludarabine. DLD1/UDG+/+ and DLD1/UDG-
/- cells were treated with fludarabine (0-40 μM) for 24 hrs. DNA was extracted and ara-
AP sites were measured using ARP. B, The formation of ara-AP sites in DLD1/UDG+/+  
cells after exposure to fludarabine (0-40 μM) for 24 hrs. DNA was extracted and divided 
in two samples.  In one sample, ara-AP sites in 10 μg of DNA were measured using ARP. 
In the other sample, 10 μg of DNA were incubated with 5U of purified E. Coli UDG, for 
2 hrs at 37 °C and subsequent ara-AP sites formed were labeled with ARP. C, Ara-AP 
sites in DLD1/UDG-/- cells with or without incubation with purified UDG. 
 
 
 
108 
  A 
0
1
2
3
4
5
6
0 5 10 20 40
DLD1/UDG+/+ 
DLD1/UDG-/-
Fludarabine (μM)
AP
 s
ite
s 
re
la
tiv
e 
to
 c
on
tro
l
 
 
 
 
  B 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
0 10 40
24h 
24h +purified UDG
AP
 s
ite
s 
re
la
tiv
e 
to
 c
on
tro
l
Fludarabine (μM)
DLD1/UDG+/+
AP
 s
ite
s 
re
la
tiv
e 
to
 c
on
tro
l
 
 
 
 
  C 
0
2
4
6
8
10
12
14
16
0 10 40
24h 
24h +purified UDG
AP
 s
ite
s 
re
la
tiv
e 
to
 c
on
tro
l
Fludarabine (μM)
DLD1/UDG-/-
AP
 s
ite
s 
re
la
tiv
e 
to
 c
on
tro
l 
 
 
 
 
 
 
109 
   4.3.2.     Up-regulation of cellular BER proteins after drug-treatments 
 In order to characterize the involvement of BER proteins in process of DNA 
damage induced by fludarabine alone or in combination with MX, we next evaluated the 
expression of BER proteins including UDG, APE, FEN1 and pol β in Jurkat and HL-60 
cells before and after drug treatment. The altered expression of BER proteins displayed a 
similar pattern in response to the drug treatment in these two cell lines. UDG, FEN1 and 
pol β were up-regulated in varying degrees after exposure to either fludarabine alone or in 
combination with MX. As shown in Figure 4-4. A, a significant induction of UDG was 
seen in cells treated with the combination of fludarabine and MX when compared with 
cells  treated with fludarabine alone (3 folds increase based on densitometric analysis) 
and the up-regulated UDG protein remained over a period of 72 hrs. It was noted that 
UDG was slightly induced by MX alone at 72 hr after treatment in these two cell lines. It 
is likely that the binding of MX to endogenous AP sites may stimulate UDG expression. 
APE expression remained unchanged before and after drug treatment in cells, indicating 
that either MX as a chemical compound or a MX-bond AP-site as a type of DNA damage 
has no direct effect on APE (24, 25) and thus are not accompanied by the upregulation of 
expression of this enzyme. APE can no longer recognize MX-bound AP site as a 
substrate, leading to further inhibition of BER process. The expressions of several other 
glycosylases, such as MPG, MBD4, TDG, AAG and Ogg1 were measured. No 
significant changes were observed in the expression levels of these glycosylases (Figure 
4-4. B). These results, together with one obtained from the enzymatic activity assay (no 
cleavage activity observed, Chapter 3), suggest that the above mentioned glycosylase are 
not involved in the recognition and removal of incorporated fludarabine. 
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Moreover, to characterize the UNG gene transcript before and after the treatment with 
fludarabine alone and fludarabine plus MX, a real time RT-PCR assay was used. The 
values obtained for the target gene using TaqMan MGB probes were normalized to β-
actin values (endogenous control) for each sample. As shown in Figure 4-4. C, a 2 fold 
increase in UNG transcript levels was observed for each time point, after fludarabine plus 
MX treatments. Similar up-regulation in the protein expression levels was measured 
using western blot analysis as described above, suggesting that MX-bound AP-sites may 
be able to trigger UNG transcription and translation, to overcome the repair inhibition. 
Furthermore, using immunofluorescence staining with UDG specific antibody, we 
confirm the up-regulation of UDG expression levels as well as nuclear localization of the 
protein after treatments with combined agents (Figure 4-4.D). 
 Although it is not clear yet for the exact mechanisms of induction of BER 
proteins, the results suggest that the expression of these BER proteins are up-regulated in 
response to the DNA damage formed by fludarabine and the combination of two drugs. It 
is apparent that up-regulation of UDG indicates the involvement of this DNA glycosylase 
in removing incorporated fludarabine as an aberrant base. Elevated poly β and FEN1 may 
suggest that MX-AP sites stall short patch BER process and simultaneously activate long 
patch BER, leading to upregulation of the key enzymes to pass through this blockage of 
repair pathway. 
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Figure 4-4 
Induction of expression of some BER proteins and UNG mRNA levels 
A, HL60 and Jurkat cells were continuously treated with drugs (5 μM fludarabine alone 
and fludarabine plus 3 mM MX) and collected at 24, 48 and 72 hrs. Cell lysates were 
subjected to western blot analysis with UDG, APE, FEN1, polymerase β, PCNA and 
tubulin specific antibodies. Control (lane 1), fludarabine alone (lanes 2,4,6), fludarabine 
plus MX lanes (3,5,7), MX alone (lane 8). B, No changes in the expression levels of other 
glycosylase before or after treatment of Jurkat cells with fludarabine and fludarabine plus 
MX. Cell lysates were subjected to western blot analysis with MPG, MBD4, Aag, TDG, 
OGG1 and tubulin specific antibodies. C, Folds increased relative to control of the UNG 
mRNA expression levels in Jurkat cells. D, Induction and localization of UDG in nucleus 
after treatment with fludarabine (5 μM) plus MX (3 mM) for 24 and 48 hrs. Cells were 
stained with UDG antibodies (green) and Hoersch dye (blue).  
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4.3.3. MX enhances fludarabine-induced DNA strand breaks 
 Previous data showed that the combination of MX and alkylating agents, BCNU 
or TMZ, increased DNA strand breaks, leading to cell death (25, 26, 30, 36).  To 
determine the induction of DNA damage induced by fludarabine alone or in combination 
with MX, the comet assay was introduced. Comet assay has been shown to be a sensitive 
and reliable measure of DNA strand breaks, AP sites, and incomplete excision repair 
sites. Comet images of Jurkat cells are presented in Figure 4-5. A. DNA damage in a 
single cell was assayed by both alkaline and neutral electrophoresis to detect single and 
double strand breaks, respectively. After treatment of Jurkat cells with fludarabine (0-20 
µM) plus MX (3 mM) for 4 hrs, distinct comets were observed compared to fludarabine 
alone. Tail length determined by neutral comet assay (the appropriate parameter to 
quantitate DNA damage for this condition, as indicated by manufacturer’s guidelines) was 
~3-fold higher in cells treated with the combination of fludarabine and MX than that 
produced by fludarabine alone, P< 0.05 (Figure 4-5. B). The increased DNA double 
strand breaks were also observed with the duration of exposure to the combination of 
fludarabine (5 µM) and MX (3 mM).  In contrast, tail moment determined by alkaline 
comet assay that measures DNA single strand breaks showed less differences in cells 
between the treatments with fludarabine alone and the combination in both dose and time 
dependent assays (Figure 4-5. C). Similar enhancement of fludarabine induced DNA 
strand breaks by MX was also observed in other three cancer cell lines, including HL60, 
U937 and SW480 (data not shown).  
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Figure 4-5 
MX enhances single and double strand breaks in  
lymphoma cells treated with fludarabine 
A, Comet images assayed by neutral and alkaline electrophoresis. Jurkat cells were 
treated with fludarabine alone (5 μM) or fludarabine plus MX (3 mM) for 4 hrs. B, 
Tail length of the comet detected by neutral electrophoresis in Jurkat cells after 
treatments with fludarabine alone (0-20 μM) and fludarabine plus MX (3 mM) and 
Tail length of comet detected by neutral electrophoresis at different times (4-24 hrs) 
after Jurkat cells treated with 5 μM fludarabine or fludarabine plus 3 mM MX (* 
P<0.05, compared with the treatment with fludarabine alone). C, Tail moment of the 
comet detected by alkaline electrophoresis in Jurkat cells with the same treatments as 
described in B. Results represent the mean values of data from three independent 
experiments. 
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         4.3.4.      MX potentiates anti-tumor effect of fludarabine in vitro 
 To correlate DNA damage such as ara-AP sites and DNA strand breaks with the 
killing effect induced by the drug treatments, cell death was assayed. The potential of 
survival and cell growth were examined in cells treated with fludarabine in absence or 
presence of MX. Considering the fact that therapeutic efficacy of alkylating agents 
enhanced by MX was extensively studied in human colon tumor models, to establish the 
therapeutic strategy that allows for comparison between the combination of MX with 
alkylating agents and fludarabine, SW480  and RKO cells was selected and treated with 
fludarabine alone and the combination with MX. Clonogenic Survival assayed in SW480 
cells (Figure 4-6. A) revealed that MX enhanced fludarabine-cytotoxicity, showing that 
the IC50 values for fludarabine was reduced from 13 μM to 6 μM by MX (DMF = 2.5, 
p<0.05). RKO cells were more sensitive to fludarabine alone (IC50 = 8 µM). Co-treatment 
with 3 mM MX sensitized cells to fludarabine with a dose modification factor (DMF) of 2 
for RKO. HL60 and Jurkat cells were treated with fludarabine (5 µM) or fludarabine plus 
MX (3 mM) and the viable cells were counted using tryptan blue exclusion every 24 hrs 
for 5 days. Marked differences in cell growth were observed between the treatment of 
fludarabine in absence or presence of MX (Figure 4-6. B). At day 5, ~ 50 % HL60 cells 
and ~ 60 % of Jurkat cells remain viable after fludarabine alone, in contrast, the 
combining fludarabine and MX significantly decreased the survival of cells; only 13.3 % 
in HL60 and 24 % in Jurkat cells survived. The augment of cytotoxicity of fludarabine by 
MX in these leukemia cells was also about 2.5 – 3.0 folds (p<0.02). 
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Figure 4-6 
MX potentiates therapeutic effect of fludarabine in tumors cells 
 A. Comparison of the cytotoxicity induced by fludarabine alone (0-20 μM) and the 
combination of fludarabine and MX (3 mM) in tumors cells assayed by clonogenic 
formation assay (SW480, RKO). B, Myeloid leukemia cells (HL60) and C, Lymphoma 
cells (Jurkat) were treated with 5 μM fludarabine and fludarabine plus 3 mM MX and cell 
viability was determined by tryptan blue exclusion. Cell viability is expressed as 
percentage of untreated control (growth inhibition assay).  
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    4.3.5.     MX potentiates anti-tumor effect of fludarabine in vivo. 
 The therapeutic efficacy of this combination was further evaluated in xenografts of 
HL60, U937 and SW480 cells in nude mice. When the tumor volumes reached 100-150 
mm3 mice were divided into control and treatment groups (6-9 mice/group). Mice 
received a single i.p. daily injection of fludarabine alone (15 mg/kg), MX (2 mg/kg) alone 
or the combination of the two drugs (fludarabine 15 mg/kg and MX 2 mg/kg), for 5 
consecutive days. Tumor responses were determined by tumor growth delay. As shown in 
Figure 4-7 , a moderate sensitivity to fludarabine was observed in both xenografts, but 
combined treatment significantly reduced tumor growth. HL60 xenograft treated with 
PBS for 17 days had a mean tumor volume of 2500 106 mm3 compared with a mean 
tumor volume of 1456 76 mm3 and 643±142 mm3 (P< 0.05) in mice treated with 
fludarabine alone or in combination with MX, respectively. Similarly, MX enhanced the 
tumor inhibitory effect of fludarabine was observed in U973 and SW480 xenografts. The 
tumor growth delays were 11±0.6 days for HL60, 9±1.1 days for U973 and 10± 0.9 for 
SW480 (P< 0.05). At these doses, mice did not present any evidence of toxicity, evaluated 
by measurements of the body weight and whole blood toxicity analysis.  
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Figure 4-7 
MX potentiates therapeutic effect of fludarabine in human xenografts 
Methoxyamine enhanced antitumor effect of fludarabine in human xenografts (HL60, 
U937 and SW480). * P<0.05 compared with the treatment with fludarabine alone.  
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4.4.      Discussion 
 We demonstrated that (i) the incorporation of fludarabine is processed by BER 
mechanism, resulting in formation of ara-AP sites (ii) MX-blocked repair of ara-AP-sites 
produced by fludarabine increases cell death through the blockage of BER, identifying a 
new mechanism for fludarabine; (iii) MX potentiates the therapeutic efficacy of 
fludarabine, developing a novel therapeutic strategy to combine inhibitor of BER with 
fludarabine for clinical treatment.  
Incorporation of fludarabine into DNA initiates the process of BER. As presented in 
Chapter 3 by using oligonucleotide substrates containing F-ara-A residues, in vitro and ex 
vivo UDG excised incorporated F-ara-A from DNA. This enzymatic action by UDG will 
probably result in formation of an ara-AP-site in the DNA. Therefore, AP sites in DNA, 
as the intermediates generated during base excision repair of abnormal bases, are the 
indicators of activated BER pathway. In this study we demonstrated that ara-AP site 
formation is proportional with fludarabine dose and time-exposure, indicating that 
incorporated fludarabine is substrate of BER. This was further supported by studies 
demonstrating that a fludarabine dose dependent formation of ara-AP sites was detected 
in cells expressing UDG but not in their counterparts, in which expression of UDG has 
been genetically turned off through UNG gene knockout. When genomic DNA of these 
UNG-/- cells treated with fludarabine was in vitro reacted with purified UDG, a significant 
increase in AP sites was measured. These results provide further evidence of the role of 
UDG as well as the involvement of BER in processing incorporated fludarabine in cell. 
However, we can not rule out the possibility of other glycosylases that may also have the 
activity excising F-ara-A from DNA in cells, considering the fact that several DNA N-
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glycosylases have been identified in mammalian cells and that each excises a specific 
damaged base with high specificity but allows some overlapping substrates (37).   
MX binds to ara-AP sites to block BER. BER is the most pro-active repair pathway that 
corrects DNA modifications arisen either spontaneously or from attack by reactive 
chemicals and anticancer agents. BER is an essential repair pathway to maintain genome 
stability and normal development, and is quantitatively an important mechanism of DNA 
repair, by which drug resistance to variety of agents occurs. Thus, balanced expression of 
BER proteins is crucial for a proper repair activity.  
MX has been developed as a blocker of BER to potentiate cytotoxicity of 
alkylating therapeutic agents such as TMZ and BCNU (24-27, 30). The action of MX to 
block BER pathway is through the binding of an aldehyde group in an AP site, the 
tautomeric open-ring form of deoxyribose. This biochemical reaction converts a 
repairable AP-site into MX-bound AP-site. This DNA lesion is refractory to the lyase 
activity of APE and poly β, consequently blocking the BER pathway. Our results 
presented in Figure 4-2. confirmed the role of MX in binding to ara-AP sites formed by 
fludarabine and the ability of MX-bound AP-sites to block repair of APE. Another 
important validation link of the involvement of BER in response to the DNA damage 
induced by the therapeutic treatment with fludarabine alone or in combination with MX 
was the findings of induction of several BER proteins, including UDG, poly β and FEN1 
in cells. UDG was significantly up-regulated after drug treatments, especially in cells 
treated with combination of fludarabine and MX. Based on the observation that UDG has 
a higher affinity for the products of AP-site than the actual substrate itself (44), it has been 
proposed that subsequent to base release, UDG remains quickly rebound to the AP site to 
124 
protect the cell until the AP site was conveyed to APE and poly β, the next enzymes in the 
BER-pathway. Thus one possible explanation for induction of UDG by fludarabine and 
MX is that the persistence of MX-bound AP-sites results in the accumulation of UDG at 
un-repairable MX-bound AP-sites. DNA poly β is known to be the polymerase of choice 
and limiting factor for the short patch BER due to its dual enzymatic activity, and FEN1 
recognizes and cleaves the single stranded DNA ‘flap’ structures during the long patch 
repair process.  Thus, the elevated poly β and FEN1 suggest that MX-bound ara-AP-sites 
impact on both short and long patch BER (18). Although the mechanisms of regulation of 
BER proteins by the drug treatments are not clear yet, results suggest that BER proteins 
have an adaptive response to DNA damage that is exaggerated by the combination of 
fludarabine and MX. One possibility would be that the unrepaired damage, MX-bound 
AP-sites is recognized by protective proteins such as Akt which will lead to activation of 
several transcription factors. Another possible mechanism is again mediated by MX-
bound AP sites that can not be further process by BER which will lead to increase 
transcription of the proteins involved in the repair process. 
Lethal DNA lesions induced by the combination of fludarabine and MX contribute 
to cell death. Combining fludarabine with MX indeed increased lethal cytotoxicity in 
comparison with fludarabine alone. The combination produced higher levels of DNA 
strand breaks and more cell death that were related to the persistence of MX-bound AP-
sites. We have previously demonstrated that MX-bound AP-sites are stable DNA lesions 
that can stall DNA synthesis, showing S phase arrest in cells after treatments. Cellular 
responses to the replication stalling by the combination of MX and alkylating agent such 
as TMZ (24) were accompanied by varying amounts of interphase nuclear DNA breaks 
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and associated metaphase chromosomal aberrations (i. e., chromosome fragmentation and 
sister chromatin exchange events). We have also reported that MX-bound AP-site acts as 
a topo II poison to trap topo II in DNA cleavage complex, resulting in topo II mediated 
DNA strand breaks and apoptosis (31). Thus, MX-bound AP-sites lethally cause cell 
death in many ways. 
Although fludarabine is widely used to treat hematological malignancies, the 
therapeutic effect has been limited by several factors. For example, the major cytotoxic 
effect of fludarabine appears to be specific to replicating cells, which may result in less 
effective of fludarabine in indolent diseases because these tumor cells are usually 
quiescent (10,42). Fludarabine can induce cell cycle arrest and apoptosis that is thought to 
act primarily through the activation of p53. However, p53 is the most commonly mutated 
tumor suppressor gene in human cancer. Tumor cells carrying an inactivating mutation of 
p53 have been reported to be resistant to fludarabine (43, 44). Thus, MX enhanced-
therapeutic efficacy of fludarabine by blocking BER should be promising with merits to 
overcome these resistant factors. Obviously, blocking BER induced cytotoxicity is non 
cell cycle specific, because BER mechanism is active throughout the entire cell cycle. 
Therefore, the potentiation of fludarabine by MX can be expected to be effective on both 
proliferating and resting tumor cells. Importantly, we demonstrated that MX enhanced 
fludarabine cytotoxicity in HL60 and Jurkat cells. These two cell lines are p53 deficient 
and Jurkat has the defect in function of mismatch repair (MMR). Thus, the potentiation by 
MX is independent of p53 and MMR status, which agrees with our previous observations 
(24, 26). 
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Implications of cancer treatment. The studies presented here suggest a viable 
synergistic approach for enhancing fludarabine cancer therapy involving disruption of 
base excision repair. Targeting BER-based therapeutic strategy can be extended to the 
combination of MX with any drugs that produce abnormal bases to incorporate into DNA 
either through acting as the nucleotide analogs or manipulating the nucleotide pools. 
Overall, this therapeutic strategy could improve both therapeutic index by decreasing the 
dose of anticancer drugs and therapeutic efficacy for the treatment of hematological 
malignancies.   
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CHAPTER V  
MITOCHONDRIAL MEDIATED CELL DEATH INDUCED BY 
FLUDARABINE COMBINED WITH METHOXYAMINE DUE TO 
BLOCKAGE OF BASE EXCISION REPAIR PATHWAY 
 
 
 
Abstract 
 Nuclear and mitochondrial DNA are constantly being exposed to damaging agents 
from endogenous and exogenous sources. To ensure viability of cells, elaborate 
mechanisms of DNA repair are essential for both nuclear and mitochondrial DNA 
(mtDNA). We have previously shown that base excision repair (BER) is activated by the 
fludarabine induced DNA damage. Methoxyamine (MX), an inhibitor of BER is able to 
enhance fludarabine cytotoxicity in cancer cell lines and human xenografts. The process 
of mitochondrial BER (mtBER) is very similar to that in nuclei, thus we hypothesize that   
mtDNA is also a target for fludarabine and MX and may represent an important aspect of 
cell death. We have demonstrated that dose dependent fludarabine treatments resulted in 
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proportional formation of mitochondrial AP sites, which are formed after the first step in 
mitochondrial BER. These mtAP-sites were efficiently bound by MX. MX-bound AP-
sites may become stable DNA lesions that have the potential to interrupt mtBER 
mechanism, leading to apoptotic cell death. These events were accompanied by a 
concomitant increase cleavage of PARP and caspase 9, loss of mitochondrial membrane 
potential (JC-1 staining) and integrity and enhanced expression levels of proapoptotic 
mitochondrial proteins (e.g., Bax.). Together, our findings suggest a mitochondrial 
mediated apoptotic death after fludarabine and MX treatments. 
 
5.1      Introduction 
 Many of the effective chemotherapeutic agents such as nucleoside analogues have 
mechanisms of action that target DNA. The ability of tumor cells to tolerate DNA 
damage and maintain their viability after treatments may contribute to reduce the 
desirable, cytotoxic outcome. Therefore, elucidating the mechanism that sense and repair 
DNA damage and targeting this mechanism is essential for development of more 
effective therapeutic strategies.  
Fludarabine, an adenosine analogue, is effective in the treatment of the 
hematological malignancies such as chronic lymphocytic leukemia and non-Hodgkin’s 
lymphoma (1, 2). Fludarabine is a potent inhibitor of DNA synthesis through the actions 
of its triphosphate metabolite, F-ara-ATP (3-8). F-ara-ATP incorporates into replicating 
strand causing reduced DNA synthesis. We have previously reported that a major DNA 
repair pathway, base excision repair, is involved in the cell response to fludarabine 
treatments, through the enzymatic activity of uracil-DNA glycosylase (9). Furthermore, 
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we have shown that methoxyamine (MX), a known inhibitor of BER, enhanced antitumor 
effect of fludarabine in vitro and in human tumor xenografts. MX binds to arabinosyl 
(ara)-AP sites formed by fludarabine and turn the repairable DNA damage into lethal 
lesion, leading to cell death. However, the molecular mechanism by which cells are killed 
by the combined treatment, fludarabine and MX is largely unknown.  
 Apoptosis, the most common form of cell death, is known to occur via an 
extrinsic (death receptor-ligand) or intrinsic (mitochondrial-centered) pathway (10). The 
apoptotic cascade is characterized by the activation of cysteine proteases called caspases, 
which cleave proteins essential for the survival of the cell. These caspases activate the 
endonucleases responsible for the internucleosomal cleavage of genomic DNA (11). 
Mitochondria play a key role in the events leading to caspases activation in cell 
undergoing apoptosis (12). Cell death at the mitochondrial level is initiated by alteration 
of the mitochondrial membrane which induce release of cytochrome c in cytosol where 
forms a complex with Apaf1 (apoptotic protease activating factor-1), ATP and inactive 
initiator procaspase-9, called the apoptosome (13-15). This complex is sufficient to 
recruit and activate caspase-9. Once activated, caspases-9 cleaves the downstream 
caspases (16,17). Death initiated by mitochondria is regulated by members of the Bcl-2 
family (18).  
 In our studies, we note that treatments with fludarabine and MX resulted in a 
significant percentage of cells that undergo apoptosis. We propose that mitochondrial 
DNA (mtDNA) may also be an important target for fludarabine and MX, in addition to 
the conventional target, nuclear DNA (9) and together, these two DNA damage signals 
contribute to induction of mitochondrial mediated apoptosis.    
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 Mt DNAs, 16.5 kb circular DNA molecules, have their own DNA repair systems 
(19). Mitochondrial BER (mtBER) pathway is very similar to the nuclear pathway and 
includes four distinct steps: lesion removal by a glycosylase, AP sites processing by an 
AP-endonuclease, insertion of a new nucleotide by polymerase γ and ligation by a DNA 
ligase (20-25). Thus, we propose that mtBER may be activated in response to fludarabine 
induced mtDNA damage. If MX binds mtAP-sites and thereby blocks the BER pathway 
in mitochondria, the level of damage induced by fludarabine will eventually become 
severe leading to lost of mitochondria ability to maintain their membrane potential and 
then activate apoptotic death pathway.           
                                                                                                                                                                        
5.1.1. Hypothesis and Rationale  
Research focus: To delineate the contribution of mitochondrial apoptotic pathway 
in cell death after fludarabine and MX exposure.   
 We hypothesized that cell death induced by fludarabine and MX is increased due 
to apoptotic signals emanating from mitochondrial DNA damage (Figure 5-1.). 
 We have examined whether fludarabine targets mtDNA and whether fludarabine 
is a substrate for mitochondrial BER. We also evaluated if MX is able to bind 
mitochondrial AP sites, thus blocking the repair pathway. Fludarabine and MX 
treatments resulted in a mitochondrial mediated apoptotic death.  
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Figure 5-1 
Working model: mitochondrial BER response to Fludarabine-induced DNA damage 
which triggers mitochondrial mediated apoptotic cell death 
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 5.2.     Materials and Methods 
        5.2.1.      Cells and reagents  
 Human tumor cell lines, Jurkat (lymphoblastic) and HL60 (myelocitic leukemic) 
used in these studies were obtained from the American Type Culture Collection 
(Rockville, MD) and cultured in proper mediums. Fludarabine was obtained from Berlex 
Laboratories (Richmond, CA) and freshly prepared with mediums (containing alkaline 
phosphatase) for the treatment. Methoxyamine (MX) was purchased from Sigma 
Chemical Co (St. Louis, MO). MX was dissolved in sterilized water (pH 7.0) and stock 
solution (2.5 M) was stored at -20 ºC.  
 
         5.2.2.     Extraction of mitochondrial DNA 
 Mitochondrial DNA isolation was carried out as described previously (23) with 
some modifications. After treatments, cells were harvested and washed with PBS. The 
cell pellet was resuspended in 10 mM Tris- 10 mM EDTA buffer; 10 % SDS solution 
was added and incubated at room temperature for 10 min. RNase A was added for 15 min 
at 37 °C followed by incubation with Proteinase K for 15 min at 37 °C. 5 M NaCl was 
added to precipitate the high molecular DNA, overnight at 4 °C. The cell lysate was 
centrifuged at 12,000 rpms for 30 min at 4 °C. The supernatant was transferred to a new 
tube and the remaining cell lysate was centrifuged again for 10 min at same speed. The 
supernatants were combined and mtDNA was extracted once with phenol: chlorophorm 
(1:1 v/v) and 1:1 v/v to above lysate supernatants. The mixture was centrifuged at 6000 
rpms for 10 min. The aqueous phase was transferred to a new tube and mtDNA was 
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precipitated by adding 2 x volume of cold 100 % ethanol. The mtDNA was washed once 
and resuspended in water. 
 
         5.2.3.     AP site assay  
The AP sites were measured using ARP (aldehyde reactive probe) reagent. ARP 
and MX have the same chemical reactivity; they competitively bind to an aldehyde group 
at an AP site. Therefore, ARP only detects MX-free AP sites. The assay was performed 
as previously described with minor modifications (26-29). Briefly, cells (2x106) were 
plated and exposed to fludarabine (0-20 µM) with or without MX (3 mM). Cells were 
collected at 24 hr after treatment and dose-dependent AP sites were measured. After 
extraction, mtDNA (10 μg) was incubated with 15 µl of 1 mM ARP (Dojindo 
Laboratories, Kumamoto, Japan) in 150 µl PBS solution at 37 ºC for 15 min. DNA was 
then precipitated with 400 µl ice-cold ethanol (100 %) at -20 ºC for 20 min and washed 
with 70 % ethanol. MtDNA was dried at room temperature for 30 min and then 
resuspended in TE buffer to achieve a final concentration of 0.3 μg/100 µl. The ARP-
labeled mtDNA was then heat-denatured at 100 ºC for 5 min, quickly chilled on ice and 
mixed with an equal amount of 2 M ammonium acetate. The DNA was then immobilized 
on BA-S 85 nitrocellulose membrane (Schleicher and Schuell, Dassel, Germany) using a 
minifold II vacuum filter device (Schleicher and Schuell, Dassel, Germany). The 
membrane was baked at 80 ºC for 1 hr and incubated with 0.25 % BSA/PBS containing 
streptavidin-conjugated horseradish peroxidase (BioGenex, SanRamon, CA) at room 
temperature for 40 min with gentle shaking. ARP-labeled mtAP sites were visualized by 
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chemiluminescence (Amersham Corp, Piscataway, NJ) followed by quantitative 
densitometry using NIH ImageJ software.    
  
         5.2.4.     Detection of mitochondrial DNA damage using PCR analysis 
 Amplification products were obtained by PCR of purified mitochondrial DNA. 
Primers pairs that target human mitochondrial genome were L-primer (5' - 15717 
CTTTATTGACTCCTAGCCGCAGAC 15740 – 3’) and H-primer (5’- 3590 
CTGGTCAACCTCAACCTAGGCC 3611 -3’), which yield a product of 4467 bp (Figure 
4-2 A). Template primers, 5 μL of 10 x buffer (without MgCl2) and dH2O were mixed in 
a 0.2 ml thin-walled PCR tube and heated for 5 min at 99.9 °C. The mixture was 
immediately placed on ice, at which time the remaining reagents were added. The final 
concentrations in the 50 μL amplification cocktail were 1x PCR buffer (Invitrogen), 300 
nM each primers, 1.5 mM MgCl2, 200 μM each dNTP and 2.6 U of Taq DNA 
polymerase. The PCR cycling profile used was: a pre-PCR incubation at 94 °C for 2 min, 
then 25 cycles of 94 °C for 15 sec, 50 °C for 30 sec and 68 °C for 4 min and then to 4 °C 
using the PCR system. Controls for the PCR were performed by amplification of GAPDH 
gene. The primers used for GAPDH were the following: GAPDH sense 5’ 
GAGGGGCCATCCACAGTCTTCTG 3’ and GAPDH antisense 5’ 
CCCTTCATTGACCTCAACTACATGGT 3’ (Sigma Genosys, Woodlands, TX). The 
PCR profile for the GAPDH gene amplification was the following: 24 cycles made up by 
4 steps; 1: 4 min at 95 °C, 2: 55 s at 95 °C, 3: 55 s at 65 °C and 4: 30 s at 72 °C; followed 
by 6 min at 72 °C. An aliquot of each reaction mixture after PCR, in 6x loading buffer, 
was resolved by electrophoresis in TBE buffer at 90 V in a 0.5 % agarose gel.  
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         5.2.5.     Western blot analysis 
 Cellular protein content was quantified spectrophotometrically using the Bio-Rad 
assay. Equal amounts of proteins (30 µg) were separated by SDS-PAGE and transferred 
to PVDF membrane (Millipore Cor., Bedford, MA). After blocking in 5 % non-fat dry 
milk in TBST for 40 min at room temperature, the blots were incubated with primary 
antibody for 1 hour at room temperature. Sources of primary antibody were as follows: 
Bcl2, Bax (Santa Cruz Biotechnology, CA), cleaved caspase 9 (Cell Signaling, Danvers, 
MA), cleaved PARP (BD Pharmingen, San Jose, CA), γH2AX (Bethyl, Montgomery, 
Texas), α-Tubulin (Sigma-Aldrich, St Louis, MO). The primary antibody solutions were 
prepared in 1 % non-fat dry milk in TBST solution as followed: cleaved PARP 1: 1000 
v/v dilution, Bcl2 1:200 v/v dilution, Bax 1:200 v/v dilution, cleaved caspases 9 1:500 v/v 
dilution, γH2AX 1:1000 v/v dilution, and Tubulin 1:500 v/v dilution. Blots were 
incubated with HRP-conjugated secondary antibody at room temperature for 1 hour. The 
blots were visualized by ECL (Amersham Corp, Piscataway, NJ) according to the 
manufacturer instructions.  
 
5.2.6 Measurement of apoptosis by Annexin V staining 
 Cells were continuously treated with fludarabine (0-20 μM), MX (3 mM) or both 
drugs in combination and collected after 24, 48 and 72 hrs drug exposure. After two 
washes with PBS, cells were resuspended in 1 x binding buffer at a concentration of 1 x 
106/mL.  Cells were exposed at room temperature for 15 min to 5-μL Annexin V-FITC 
(BD Bioscience, San Jose, CA) following the instructions of the manufacturer. Analysis 
was carried out with FACSort (Becton Dickinson & Co., Mountain View, CA). 
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5.2.7.    Cytofluorometric analysis of mitochondrial transmembrane potential 
(ΔΨm) by JC1 
 JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazoyl carbocyanine iodide, 
Cell Technologies, Mountain View, Ca) is a lipophilic cationic dye that enters the inner 
mitochondrial matrix in its monomeric form when the mitochondrial membrane is 
polarized (Reers et al., 1991, 1995). Cells were treated with the indicated amounts of 
drugs either alone or in combination for 24 hrs. Cells were then washed with 1 x  assay 
buffer and incubated for 15 min at 37  ºC with 1x JC1  reagent. In healthy cells the dye 
stains the mitochondria bright red. In the apoptotic cells, the mitochondrial membrane 
potential collapses and the JC1 reagent cannot accumulate within the mitochondria. In 
these cells JC1 remains in the cytoplasm in a green fluorescent monomeric form. The red 
form has absorption/emission maxima at 585/590 nm, while the green monomeric form 
has absorption/emission maxima at 510/527 nm. Cells were analyzed on FACSCalibur 
(Becton Dickinson, San Jose, CA) flow cytometer. 
 
         5.2.8.      Immunofluorescence microscopy 
 Cells were grown on a 6 wells plate and were treated with fludarabine and 
fludarabine plus methoxyamine for 24 and 48 hrs. At each time point, cells were washed 
with PBS and incubated with 250 nM MitoTracker (Molecular Probes, Carlsband. CA) at 
37 °C for 45 min. Then, cells were washed twice with PBS and cytospin on a slide at 600 
g, for 8 min. Both treated and untreated cells were fixed in 2 % paraformaldehyde and 
permeabilized with 0.2 % Triton X-100. Cells were incubated with primary cytochrome 
C antibody (Santa Cruz) for 1 hrs at room temp, followed by secondary antibody 
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conjugated to Alexa 488 (green) (Molecular Probes, Carlsband, CA). Nuclei were stained 
using Hoersch dye, 2 mg/ml, for 30 min at room temperature. Images were digitally 
captured using an Olympus microscope equipped with a digital camera.  
 
5.3.      Results 
         5.3.1.      Exposure to fludarabine alone and in combination with MX leads to    
mtDNA damage  
 Previous studies have reported that one class of nucleotide transporter (hENT1) is 
localized in the mitochondrial compartment (30). Several nucleotide analogues have been 
shown to use hENT1 transporter to target mtDNA (31). However, it is not clear whether 
fludarabine is actively transported into mitochondrial and subsequently induces mtDNA 
damage. In these studies we employed a PCR based method to measure the mtDNA 
damage after drug treatments. HL60 and Jurkat cells were treated with fludarabine alone 
(0-80 μM) or fludarabine plus MX (3 mM) and harvested at 24 hr. Total DNA and 
mtDNA was isolated and analyzed by PCR with primers that amplify a 4.4 kb segment of  
mitochondrial genome (Figure 5-1. A) or GAPDH primers (for control). As Figure 5-2. B 
shows, a substantial reduction in the 4.4-kb amplification product corresponding to the 
mitochondrial genome was detected with DNA isolated from Jurkat cells treated with 
increase concentration of H2O2. H2O2 is a known agent proved to induce extensive 
mitochondrial DNA damage. We used this treatment as a positive control to validate our 
method. We use GAPDH as a control for our PCR reactions.  
When the same cells were treated with fludarabine for 24 hr, a decrease of 30 % in 
amplification signal was observed at the highest concentration of fludarabine, while a 
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more significant decrease in amplification was measured when cells were treated with the 
combination of fludarabine and MX. A 30 % decrease was observed at 10 μM 
fludarabine plus 3 mM MX which reached 54 % decrease at the concentration of 40 μM 
(Figure 5-2. C). Similar results were obtained when HL60 were incubated with 
fludarabine or fludarabine plus MX and assessed for mtDNA damage. Fludarabine alone, 
at very high concentration (100 μM) resulted in a 50 % reduction in amplification signal, 
while the same concentration of fludarabine plus 3 mM MX resulted in a very significant 
decrease in the amplification rate (76 %) (Figure 5-2. D). These results prove that the 
combination of fludarabine and MX targets mtDNA resulting in overall reduced 
amplification suggesting the presence of mtDNA damage that cannot be overcome by the 
polymerase employed in the PCR reaction.  
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Figure 5-2 
Detection of mitochondrial DNA damage induced in the presence of fludarabine 
plus MX 
 A,  The length and localization of the PCR amplification product in the human 
mitochondrial genome B, PCR amplification products were resolved in 0.5 % agarose gel 
and visualized by ethidium bromide staining. A representative picture shows a reduction 
in the 4.4 kb product corresponding to the mitochondrial genome. Amplification was 
done with DNA from Jurkat cells incubated with H2O2 (0-800 μM) for 1 hr and collected 
24 hr after treatment. Amplification of the GAPDH served as a control for the PCR. C, 
Jurkat cells were treated with fludarabine (0-80 μM) or fludarabine plus 3 mM MX for 24 
hr and mtDNA damage was measured. Vertical bars measure relative amplification based 
on the density of the bands that is inversely proportional to the extent of DNA damage D, 
HL60 cells were treated with fludarabine (0-100 μM) or fludarabine plus 3 mM MX for 
24 hr and mtDNA damage was measured. 
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         5.3.2.   Formation of ara-AP sites in mitochondrial DNA after exposure to                        
fludarabine alone and in combination with MX 
The above experiments confirm that the combination of fludarabine and MX 
targets mtDNA and determines mtDNA damage. Our previous studies showed that the 
MX enhancement of fludarabine-induced nuclear damage is due to binding of MX to the 
ara-AP sites formed by fludarabine and subsequent interrupts BER pathway. Considering 
that fludarabine action is mediated by the incorporation of the nucleotide analog into 
DNA strand, we hypothesize that fludarabine is incorporated into mtDNA and 
mitochondrial (mt) BER pathway is activated. Therefore, a direct assay was used to 
measure the mtBER response after fludarabine, by measuring mitochondrial ara-AP sites 
using ARP. ARP has been demonstrated to have similar chemical structures to MX and 
can specifically bind to an aldehyde group in an AP site (27, 32). Tumor cells were 
treated with fludarabine alone (0-20 μM) or fludarabine plus MX (3 mM) and harvested 
at 24 hr. MtDNA was extracted and mtAP-sites were measured. Results showed 
formation of that mtAP-sites proportional with fludarabine concentrations, in the two 
cancer cell lines used HL60 and Jurkat (Figure 5-3. A & B).  Co-treatment with 3 mM 
MX reduced by 2-4 folds the detectable mtAP-sites (Figure 5-3. A & B). This reduction 
of mtAP-sites is presumably due to the binding of MX to the aldehyde group of the 
mtAP-sites to form MX-bound AP-sites, making the mtAP-sites unavailable for ARP. 
Importantly, these results indicate that MX is capable of blocking mitochondrial repair of 
fludarabine-induced damage. These results are also in agreement with our PCR analysis 
results of mtDNA damage which showed increased damaged when cells were treated 
with the combination of the two drugs. 
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Figure 5-3 
Fludarabine induces formation of mitochondrial ara-AP sites that are bound by MX 
A, The dose-dependent relationship between the levels of mtAP-sites and the 
concentrations of fludarabine. The ara-AP sites in mtDNA were measured using ARP 
reagent after Jurkat cells were treated with fludarabine alone (0-20 μM) or in combination 
with MX (3 mM) for 24 hrs (* P<0.05 compared to fludarabine alone). B, The dose-
dependent relationship between the levels of mtAP-sites and the concentrations of 
fludarabine (0-20 μM) or fludarabine plus MX (3 mM) for  24 hr in HL60 (* P<0.05 
compared to fludarabine alone). Results represent the mean value of data from three 
independent experiments. 
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 B.  Jurkat cells 
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5.3.3. MX enhances fludarabine induced apoptosis 
 To correlate mtDNA damage such MX-bound mtAP-sites with the killing effect 
induced by the drug treatments, apoptotic cell death was assayed. HL60 and Jurkat cells 
were treated with fludarabine (5 µM) in the absence and presence of MX (3 mM) and 
collected at 24, 48 and 72 hr after treatments. Each sample was subjected to analysis of 
apoptosis by stained with Annexin V and detection of expression levels of apoptotic 
proteins by western blotting assay. The results showed that fludarabine alone produced 
low percentage of apoptotic cells in HL60 and Jurkat cell lines (Figure 5-4. A) and co-
treatment of fludarabine with MX significantly increased Annexin V-positive cells. At 72 
hr the combination-treatment induced 60-70 % of cells undergoing to apoptosis, which 
was 3 to 7-fold higher than that induced by fludarabine alone in HL60 and Jurkat cells 
respectively.  We next examined proteolytic cleavage of PARP by caspases, which is a 
hallmark of apoptosis.  As shown in Figure 5-4. B, time-dependent PARP cleavage was 
seen in HL60 and Jurkat cells after drug treatment. In HL60 cells, cleaved PARP was 
detected by 48 and 72 hr of treatments with either fludarabine alone or in combination 
with MX. In Jurkat cells, cleaved PARP was significantly induced by the combination of 
fludarabine and MX. The enhanced PARP cleavage appeared to continue to accumulate 
even as late as 72 hr, suggesting that this process of caspase activation was more 
specifically activated by the combination treatment in Jurkat cells. Moreover, γH2AX, 
the marker of DNA strand break, was also remarkably induced by the combined 
treatment in both cell lines, which was consistent with the cleaved PARP, suggesting that 
DNA strand breaks produced by the combination of fludarabine and MX may signal for 
cell death. Further, we monitored the expression of several apoptotic proteins after 
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fludarabine alone or combined treatments (Figure 5-4 B) in a time dependent fashion. 
Treatment of HL60 and Jurkat cells with MX, fludarabine alone, or in combination, 
exerted little effect on expression of Bcl2, an antiapoptotic protein. In contrast, the levels 
of proapoptotic protein Bax were induced. In HL60 cells, at 24 and 72 hr, there was a 
slightly induction of Bax by fludarabine or the combination. A peak level in Bax 
expression was observed at 48 hr after combined treatments. Similarly, expression levels 
of Bax were up-regulated after treatment of Jurkat cells with fludarabine plus MX 
starting at 24 hr and persisted over 72 hr. Finally, the expression levels of 
procaspase/caspases 9, an important mitochondrial related apoptotic protein were 
determined. Treatments of HL60 cells with fludarabine alone resulted in minimal 
cleavage/ activation of procaspase 9 at 24 and 48 hr and a slightly increased effect at 72 
hr. However, the exposure of cells to fludarabine and MX resulted in marked induction of 
caspases activation. In Jurkat cells, more modest effects are measured even after the 
exposure of cells to combined treatments. 
153 
  
 
 
 
 
 
Figure 5-4 
MX potentiates fludarabine induced mitochondrial mediated apoptotic cell death 
A, The percentage of Annexin V-positive cells produced by fludarabine alone and 
fludarabine plus MX at 24, 48 and 72 hr (*P<0.05 compared with the treatment with 
fludarabine alone). B, Induction of the cleaved form of PARP, γH2AX, Bcl-2, Bax and 
caspases 9 proteins was detected by western blotting in cells after treatments with 
fludarabine alone and in combination with MX. Control (lane 1), fludarabine alone (lanes 
2,4,6), fludarabine plus MX (lanes 3,5,7), MX alone (lane 8). Results are representative 
of at least three experiments.  
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5.3.4.    Loss of mitochondrial membrane potential as a result of mitochondrial 
DNA damage induced by combined treatment  
 Induction of apoptosis, particularly by cytotoxic drugs, is intimately related to 
mitochondrial dysfunction [33]. Consequently, the effects of combined exposure to 
fludarabine and MX on mitochondrial integrity were examined. Mitochondrial membrane 
potential is a key indicator of cellular viability, as it reflects the pumping of hydrogen 
ions across the inner membrane during the process of electron transport and oxidative 
phosphorylation, the driving force behind ATP production (Figure. 5-5 A).  The lipophilic 
mitochondrial probe JC-1 was used to estimate changes in membrane potential (Δψm). 
Cells were treated with fludarabine and fludarabine plus MX for 24, 48 and 72 hr. At 
each time point, JC-1 reagent was added and cells were analyzed by flow cytometry for 
polymeric (intramitochondrial) and monomeric (cytosolic) forms of JC-1. As shown in 
Figure 5-5. B exposure to fludarabine had minimally affected the transmembrane 
potential. In contrast, combined exposure MX/fludarabine resulted in a 6-fold increase in 
the fluorescence intensity for the monomeric form of the dye at 24 hr. This significant 
increase in the percentage of cells that lost their mitochondrial membrane potential after 
combined treatments lasted over 72 hr (Figure 5-5 C).  
These results are consistent with the preceding measurements of apoptotic cells and they 
indicate that exposure of leukemic cells to fludarabine and MX results in a marked 
potentiation of mitochondrial dysfunction and activation of apoptotic pathway.  
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Figure 5-5 
Fludarabine plus MX induced mitochondrial membrane potential collapse 
A, mtDNA damage can lead to decrease in electron transport and subsequent to loss of 
mitochondrial membrane potential. B, An example of the flow cytometer data for the 
drug-induced loss of mitochondrial membrane potential in Jurkat cells as determined with 
JC-1 dye. The polymeric form (intramitochondrial) is found in the top quadrant while the 
monomeric form of the dye (cytosolic) is found in the bottom quadrant. C, Jurkat cells 
were treated with 5 μM fludarabine or fludarabine plus 3 mM MX for 24, 48 and 72 hr. 
The percentage of cells that lost their mitochondrial membrane potential was determined 
using JC-1 staining and flow cytometer as described in B.  
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5.3.5. Loss of mitochondrial integrity induced by combined treatment  
 Parallel studies were carried out using Jurkat cells treated fludarabine or 
fludarabine plus MX which at 24 hr after treatment were cytospin on a slide and 
immunofluorescence stained for mitochondria with MitoTracker (MT) and cytochrome 
C. In the control cells, cytochrome C and MT co-localized in the mitochondria (Figure 5-
6). After treatments with either fludarabine or MX alone, no visible effect was observed, 
which correlated with previous published data [34]. However, when cell were treated 
with 5 μM fludarabine plus 3 mM MX for 24 hr, both cytochrome C and MT 
fluorescence signals were reduced and accompanied by disruption of the arranged 
organization of mitochondria in cytoplasm. These data are in agreement with our 
mitochondrial membrane potential data. The combination of fludarabine plus MX 
induces mtDNA damage presumably through the inhibition of mtBER that will 
eventually lead to loss of mitochondrial membrane potential and mitochondrial collapse. 
As an end point, mitochondrial-mediated apoptosis will be triggered.  
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Figure 5-6 
Immunocytochemistry of mitochondrial damaged caused by fludarabine plus MX 
treatments 
Jurkat cells were treated with indicated drugs for 24 hr. Cells were stained for 
mitochondria  with MitoTracker  (red) for 30 min , pelleted on a slide at 600 g for 8 min, 
fixed in 2 % paraformaldehyde, and stained for  cytochrome C (green) with monoclonal 
antibody (Santa Cruz) and secondary antibody Alexa 488. DNA was visualized with 
Hoersch (blue). The very right panel represents the composed images.  
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5.4.   Discussion 
 In addition to the nuclear genome, cells harbor a mitochondrial genome. 
Mitochondrial DNA exists as a 16.6 kb circular structure and contains 13 oxidative 
phosphorylation genes, two rRNAs, and 22 tRNAs. The increased susceptibility of the 
mtDNA to drug-induced damage, as compared with the nDNA, has been previously 
documented (35); however, the specific molecular causes of these phenomena are not 
well understood. It has been hypothesized that a combination of biological determinants, 
such as the proximity of the mtDNA to ROS, the lack of a compact nucleosome structure 
to protect the genome, and a paucity of mtDNA damage-processing pathways relative to 
those present in the nucleus play a role (36). Moreover, the susceptibility of mtDNA and 
the role of mitochondrial repair pathways to the damage induced by specific class of 
chemotherapeutic agents such as nucleotide analogs have been poorly investigated. 
 Previous data (chapter 3 and chapter 4) have shown that fludarabine-induced 
nuclear DNA damage activates BER.  Combining fludarabine with MX, an agent that 
blocks BER, led to significant cell death. In the present study we prove that mtDNA is a 
site for fludarabine and MX actions and we elucidated the mechanism of cell death 
induced by the combination of the two agents along with the role of mitochondria in this 
process.  
Mitochondrial BER system is activated as response to fludarabine damage. It has 
been shown that several types of mtDNA damage are repaired by a short-patch mtBER 
process (21). Here, we report for the first time that fludarabine and fludarabine combined 
with MX induced mtDNA damage. At low fludarabine concentration, the global 
assessment of mtDNA damage using PCR amplification showed minimal effects. In 
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contrast, when fludarabine was combined with MX, low amplification was measured, 
suggesting the presence of significant mtDNA damage. Also, we considered measuring a 
more specific type of mtDNA damage and that was the mtAP-site formation. Our results 
showed for the first time that fludarabine induces formation of mtAP-sites which are 
bound by MX resulting in inhibition of further mtBER. These MX-bound AP-sites 
refractory to BER will result in global mtDNA damage. 
Interruption of BER by MX results in induction of mitochondrial mediated 
apoptosis. Measurements of apoptotic cell death revealed that the combination of 
fludarabine plus MX resulted in more than additive apoptotic cell death. To determine the 
prevalence of intrinsic (mitochondrial-mediated) over extrinsic (death receptor) pathway 
in execution of apoptotic cell death, several approaches were used. 
(i) Time course analyses of mitochondrial membrane potential in whole cells 
demonstrated that fludarabine alone had minimal effect on mitochondrial integrity, as 
previously reported (37). In contrast, fludarabine plus MX treatments lead to a significant 
percentage of cells that lost their mitochondrial membrane potential. To explain this 
observation, we propose that mitochondrial MX-bound AP–sites block mtBER leading to 
accumulation of mtDNA damage. Accumulation of unrepaired mtDNA damage will 
eventually become severe, impairing the electron transport machinery along the inner 
membrane that will lead to collapse of the mitochondrial membrane potential. 
(ii) Immunofluorescence microscopy using Mitotracker, a mitochondrial staining, and 
cytochrome c antibody were conducted. The immunofluorescence images confirmed these 
results, showing a disrupted arrangement of mitochondria.  
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(iii) These events were accompanied by cleavage and activation of PARP and caspase 9. 
Also, the expression levels of proapoptotic protein Bax are up-regulated, suggesting that 
Bax is translocated to the outer mitochondrial membrane. Bax translocation to the 
mitochondria has been shown to reduce mitochondrial membrane potential, enhance 
cytochrome c release from mitochondria and activate caspases (37).  
Together, our results point out for the first time that the combination of fludarabine and 
MX targets mtDNA.  Interruption of mtBER pathway along with nuclear BER induces 
severe damage, leading to lost of mitochondria ability to maintain the membrane potential 
and subsequent activation of mitochondrial mediated apoptotic death. 
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CHAPTER VI  
DISRUPTION OF BASE EXCISION REPAIR BY METHOXYAMINE 
SENSITIZIES CHRONIC LYMPHOCYTIC LEUKEMIA CELLS TO 
FLUDARABINE  
 
 
Abstract 
 We have applied our findings on biochemical mechanisms governing fludarabine-
induced cytotoxic effects (Chapter 3-5) to test if fludarabine plus MX combination can 
improve the treatment of chronic lymphocytic leukemia (CLL). More specifically, we are 
investigating how blockage of the DNA base excision repair (BER) pathway via BER 
inhibitor, methoxyamine affects the action of the nucleotide analog fludarabine. In this 
study, we used primary CLL cells and similar experimental approach, as employed in 
previous chapters. Enhancement of fludarabine toxicity by methoxyamine was analyzed 
using in vitro assays, including AP sites assay, Comet assay to quantitate DNA damage, 
apoptosis via Annexin staining, mitochondrial membrane potential via JC1 staining and 
Western Blotting and RT-PCR analysis for protein expressions and transcript levels of 
key BER enzymes as well as apoptotic proteins. Data showed that activity of fludarabine 
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was effectively modulated by methoxyamine in CLL cells. Enhancement of fludarabine-
induced cytotoxicity was dependent on formation of nuclear and mitochondrial ara-AP 
sites by fludarabine which are bound by MX. Primary CLL lymphocytes exhibited 
intrinsically higher BER expression and activity when compared with normal 
lymphocytes. CLL cells were significantly more sensitive to the fludarabine in 
combination with methoxyamine as assayed by cytotoxicity, apoptosis, and levels of 
DNA damage. Exposure of CLL lymphocytes to fludarabine plus MX treatments resulted 
in mitochondrial-mediated apoptosis with loss of mitochondrial membrane potential and 
enhanced cytosolic release of proapoptotic mitochondrial proteins.  
This study shows that through manipulation of the BER pathway, an increase in response 
to fludarabine is achieved in CLL lymphocytes. Thus, the combination of fludarabine 
plus methoxyamine has potential for further clinical targeted therapy, with lower toxicity 
to normal cells. 
 
6.1.  Introduction 
 Chronic lymphocytic leukemia (CLL) is the most common form of lymphoid 
malignancies with a variable clinical course (1). It is manifested by progressive 
accumulation of morphological mature but immunological dysfunctional B lymphocytes. 
Outcome for advanced-stage CLL patient is poor, with an expected median survival of 
three years (2). Although the introduction of purine nucleoside analogues (3) and 
monoclonal antibody therapies such as alemtuzumab and rituximab (4,5), either as single 
or in combination regimens (6), have led to improved significant response rates, none of 
these options are curative. Consequently, there is a need for novel therapeutic strategies in 
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the treatment of CLL. 
 Fludarabine is a synthetic adenine nucleoside analog approved as the first-line 
treatment in CLL. Fludarabine is used, as a stand-alone drug, as well as in combination 
with chemotherapeutic agents such as cyclophosphamide (7,8), cytararabine (9,10) or 
cisplatin (11,12). While it has been shown to be effective in inducing complete remission, 
many patients eventually develop drug resistance leading to disease progression. 
Fludarabine is an inhibitor of DNA synthesis through the actions of its triphosphate 
metabolite, F-ara-ATP (13-19). F-ara-ATP incorporates into replicating strand causing 
reduced DNA synthesis. Although the relative contributions of diverse molecular actions 
of fludarabine to cell death remain unknown, its incorporation in the DNA strand appears 
to be required for lethality (20). We have previously shown that incorporated F-ara-A 
acts as an abnormal base in DNA and initiates base excision repair (BER) through the 
enzymatic activity of uracil DNA glycosylase (21), using tumor cell lines (Chapter 3, 
Chapter 4).  
 BER is initiated by a DNA glycosylase that recognizes and removes the 
inappropriate base with the formation of a potentially cytotoxic abasic (AP) site that is 
processed by an AP endonuclease (APE). APE incises the phosphodiester backbone 
immediate at the 5’ position to the lesion, leaving behind a strand break. Replacement of 
the damaged base and religation of the DNA involves recruitment of DNA polymerase β 
and ligase III (22-27). BER is the most efficient repair mechanism to repair a variety of 
base lesions, contributing to cells resistance to anticancer agents that produce DNA 
lesions. Thus, expression and activity of BER key proteins in CLL lymphocytes may play 
a role in development of resistance to fludarabine treatments. It also may be an important 
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factor for the development of new combinatory therapeutic strategy to target BER, with 
high selectivity toward tumors cells by exploiting the biological differences between 
normal and cancer cells. Methoxyamine (MX), an inhibitor of BER, specifically binds to 
AP sites (28-39) preventing their processing by APE and leading to accumulation of 
these cytotoxic sites in DNA. Recently, we have shown that MX improves the therapeutic 
efficacy of fludarabine in vitro and in human tumor xenografts (21). Exploring the 
combination of fludarabine and MX in the treatment of CLL is a first step toward 
developing future targeted combinatory treatment regimens.  
 An important feature of CLL cells that contributes to failure of the treatments is 
their resistance to apoptosis due to several factors such as Bcl2 overexpression or 
increase production of anti-apoptotic cytokines (40). Apoptosis, the most common form 
of cell death, is known to occur via an extrinsic (death receptor-ligand) or intrinsic 
(mitochondrial-centered) pathway, in which mitochondria play a key role in the events 
leading to caspase activation. Mitochondrial DNA is a target for damage induced by a 
variety of therapeutic agents (41-43). Even though mitochondrial DNA (mtDNA) lacks 
efficient repair systems, a simplified BER pathway have been established that is similar 
with the one in nuclei (42). Thus, in addition to nuclear DNA (the conventional target of 
fludarabine) mtDNA may also be targeted and perhaps an important mediator of 
apoptosis during mtBER disruption by MX in CLL lymphocytes.  
 The present work was designed to show for the first time that MX enhances 
fludarabine cytotoxicity in CLL. We studied the intrinsic BER expression and activity of 
CLL lymphocytes and the response to fludarabine and MX treatments. We quantified ara-
AP site formation, monitored expression levels of relevant proteins and measured 
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production of DNA strand breaks after combined treatments. We also characterized the 
nature of the cell death induced in CLL by fludarabine and MX combination. Our data 
showed that fludarabine treatment has generated dose- and time-dependent formation of 
nuclear and mitochondrial ara-AP sites in CLL cells which were bound by MX. MX-
bound AP-sites were resistant to BER and eventually led to enhanced single and double 
DNA strand breaks triggering mitochondrial mediated apoptosis. Taken together, these 
results established for the first time the basis for a possible clinical therapeutic strategy. 
 
     6.2.       Materials and Methods 
6.2.1. Reagents and enzymes 
 Fludarabine was obtained from Berlex Laboratories (Richmond, CA) and freshly 
prepared when used. Methoxyamine was purchased from Sigma Chemical CO (St. Louis, 
MO), dissolved in sterilized water (pH 7.0) at a concentration of 2.5 M (stock solution) 
and stored at -20 ºC. E. Coli Uracil DNA glycosylase (UDG) and human AP 
endonuclease (APE) were purchased from Trevigen (Gaithersburg, MD). 
 
6.2.2. Isolation and culture of primary cells 
 Peripheral blood was obtained from CLL patients and healthy donors who have 
provided written informed consent. The clinical characteristics of the patient cohort is 
summarized in Table 5-I. Heparinized peripheral blood samples were fractioned by 
Ficoll-Paques sedimentation (Sigma Chemicals, St Louis, MO). Freshly isolated 
peripheral blood lymphocytes were cultured in RPMI medium (HyClone, Logan, Utah) 
supplemented with 10 % fetal bovine serum and 1 % L-Glutamine at a density of 1 x 
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106/ml. Lymphocytes were incubated at 37 ºC in a humidified 5 % carbon dioxide 
atmosphere in the presence of fludarabine (0-20 μM), MX (3 mM) or both drugs in 
combination. In addition, control cultures with no drug added were carried out. All 
experiments were performed in duplicates.  
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Tabel 6-I. Characteristics of the 47 patients 
 
 
618Female
Age (years)
4158Median
30-6744 - 78Range
Lymphocytes counts (per μl)
8 x 103// μL69 x 103// μLMedian
5- 11 x 103// μL11 – 365 x 103// μLRange
Sex
915Male
CLL patients Normal donorCharacteristics 
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            6.2.3.   DNA glycosylase/APE assay  
 The fluorescent HEX labeled 40-mer oligonucleotide containing a deoxyuridine 
residue at position 19 and its complement strand labeled with Cy5 were synthesized by 
Operon Biotechnologies (Huntsville, Alabama). The sequences of the top and bottom 
strands were: 5’[HEX]GTAAAACGACGGCCAGTGUATTCGAGCTCGGTACCCGG 
GG (top) and 5’-[Cy5]CCCCGGGTACCGAGCTCGAATGCACTGGCCGTCGTTTT 
AC (bottom). Duplex oligonucleotides were generated by annealing the two 
complementary strands in a reaction buffer containing 10 mM Tris-HCl, 50 mM KCl, and 
1 mm EDTA, by incubation at 95 ºC for 5 min followed by  slow cooling at room 
temperature for 1 hour. The standard assay mixture for DNA glycosylase activity, 
containing 4 pmols of the fluorescent labeled duplex oligonucleotides in 20 µL buffer [1 
mM EDTA, 1 mM dithiothreitol (DTT), and 20 mM Tris-HCl (pH 8.0)] was incubated 
with purified DNA glycosylase (UDG) for 1 hr at 37 ºC. The reaction was stopped at 95 
°C for 5 min. After excising the misincorporated base by DNA glycosylase, abasic sites 
were incised by 1 unit of purified APE at 37 °C for 1 hr. Similar procedure was used to 
measure glycosylase activity of cell extracts. Substrate was incubated with cell extracts 
for 30 min, at 37 °C.  The reaction was stopped at 95 °C. Ten ml of loading buffer (300 
mmol/L NaOH, 97 % formamide and 0.2 % bromophenol blue) were added and reaction 
mixtures were heated to 95 ºC for 5 min, then cooled at 4 ºC on ice. Reaction products 
were resolved by electrophoresis through denaturing 19 % polyacrylamide gels (7 M 
urea, 1x Tris-borate-EDTA) and visualized by using a Typhoon 9200 fluorescent Imager 
(Amersham BioScience, Piscarawat, NJ). Fluorescent densities were quantified using 
ImageQuant software.  
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           6.2.4.    AP site assay  
  The AP sites were measured using ARP (aldehyde reactive probe) reagent that 
reacts with an aldehyde group at an AP sites. MX binds to the AP site at the same 
aldehyde group. Therefore, the ARP reagent only detects MX-free AP sites. The assay 
was performed as previously described (34, 44-46) with minor modifications. Briefly, 
cells (2x106) were plated and exposed to fludarabine (0-20 µM) with or without MX (3 
mM). Cells were collected at 24 hrs after treatment and dose-dependent AP sites were 
measured. Alternatively, for the time-dependent assay, cells were exposed to 5 µM 
fludarabine with or without MX (3 mM) up to 72 hrs. Cells were harvested at 12, 24, 48 
and 72 hrs, respectively. After extraction with phenol (Fischer Scientific, Fair Lawn, NJ) 
and chloroform (Sigma-Aldrich, St Louis, MO), DNA (10 g) was incubated with 15 µL 
of 1 mM ARP (Dojindo Laboratories, Kumamoto, Japan) in 150 µL PBS solution at 37 
ºC for 15 min. DNA was then overnight precipitated with 400 µL ice-cold ethanol (100 
%) at -20 ºC and washed with 70 % ethanol. DNA was dried at room temperature for 30 
min and then resuspended in TE buffer to achieve a final concentration of 0.3 g/100 µL. 
The ARP-labeled DNA was then heat-denatured at 100 ºC for 5 min, quickly chilled on 
ice and mixed with an equal amount of 2 M ammonium acetate. The DNA was then 
immobilized on BAS 85 nitrocellulose membrane (Schleicher and Schuell, Dassel, 
Germany) using a minifold II vacuum filter device (Schleicher and Schuell, Dassel, 
Germany). The membrane was baked at 80 ºC for 1 hr and incubated with 0.25 % 
BSA/PBS containing streptavidin-conjugated horseradish peroxidase (BioGenex, 
SanRamon, CA) at room temperature for 40 min with gentle shaking. The nitrocellulose 
membrane was rinsed with washing buffer containing NaCl (0.26 M), EDTA (1 mM), 
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Tris-HCl (20 mM) and Tween 20 (1 %) for 1 hr at room temperature. ARP-labeled AP 
sites were visualized by chemiluminescence (Amersham Corp, Piscataway, NJ) followed 
by quantitative densitometry analysis using NIH ImageJ software.  
           
          6.2.5.     Western blot analysis  
 Cellular protein content was quantified spectrophotometrically using the Bio-Rad 
assay. Equal amounts of proteins (30 µg) were separated by SDS-PAGE and transferred 
to PVDF membrane (Millipore Cor., Bedford, MA). After blocking in 5 % non-fat dry 
milk in TBST for 40 min at room temperature the blots were incubated with primary 
antibody for 1 hr at room temperature. Sources of primary antibody were as follows: 
cleaved PARP (BD Pharmingen, San Jose, CA), APE, Fen1, polymerase β, PCNA (Santa 
Cruz Biotechnology, CA), UDG (Abcam, Cambridge, MA), cleaved caspase 9, Bax, 
Bcl2, topoisomerase IIα (Cell Signaling, Danvers, MA), and Tubulin (Sigma-Aldrich, St 
Louis, MO). The primary antibody solutions were prepared in 1 % non-fat dry milk in 
TBST as followed: cleaved PARP 1: 1000 v/v dilution, APE 1:2000 v/v dilution, Fen1 
1:200 v/v dilution, polymerase β 1:200 v/v dilution, UDG 1:500 v/v dilution, PCNA 
1:200 v/v dilution, Bcl2 1:200 v/v dilution, Bax 1:200 v/v dilution, cleaved caspases 9 
1:500 v/v dilution, γH2AX 1:1000 v/v dilution, topoisomerase IIα  1:500 v/v dilution and 
Tubulin 1:500 v/v dilution. Blots were incubated with horseradish peroxidase-conjugated 
secondary antibody (1:1000 v/v dilutions in 1 % non-fat dry milk in TBST) for 1 hr. The 
blots were visualized by ECL (Amersham Corp, Piscataway, NJ) according with the 
manufacturer’s instructions.  
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          6.2.6.    RT-PCR assay 
 Total RNA was isolated from ~5 x 106 lymphocytes using RNAqueous-4PCR kit 
(Ambion, Austin, TX) according with the manufacturer’s instructions. The extracted 
RNA was quantitated by measuring absorbance at 260 nm using NanoDrop100 
spectrophotometer (Thermo Scientific, Wilmington, Delaware). Then cDNA was 
synthesized from 5 μg of total RNA in a 20 μL reaction mixture according to the 
manufacturer’s instructions using SuperScript III first strand kit (Invitrogen, Frederick, 
Maryland) with random hexamers. The thermal profile of the reaction was set for stage 1: 
10 min at 25 ºC; stage 2: 50 min at 50 ºC and stage 3: 5 min at 85 ºC.  TaqMan MGB 
probes (FAMTM dye labeled) for nuclear UDG (NM 080911.1), topoisomerase IIα 
(NM001067.2) and β-actin (NM001101.2) were used. To amplify the cDNA, 0.25 μg of 
the reversed transcribed cDNA from cells were subjected to 40 cycles of PCR using 
TaqMan one-step RT-PCR master mixture reagent kit in a 96-well optical plate. The 
cycling parameters in an ABI 7500 Fast Real-Time PCR System (Applied Biosystem, 
Foster City, CA) were as follows: stage 1: 50 ºC for 2 min; stage 2: AmpliTaq activation 
95 ºC for 10 min; stage 3: 40 cycles of amplification at  95 ºC for 15 s and stage 4: 60 ºC 
for 1 min. The amount of target was calculated after normalization to the β-actin as an 
endogenous control. 
 
          6.2.7.     Measurement of Cell Growth 
 Lymphoma cells were seeded at a density of 5×105 cells/well in 6-well plates 
in the presence of 10 % (v/v) fetal bovine serum. Cells were treated with various 
concentrations of fludarabine (5-20 μM) or fludarabine plus MX (3 mM). Viable 
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cells were counted daily, for 5 days, in a hemocytometer (10 µL of cell suspension), 
using tryptan blue exclusion.  
 
         6.2.8.     The alkaline and neutral single cell gel electrophoresis (Comet) assay 
 The single cell comet electrophoresis assay was performed using Comet Assay kit 
(Trevigen, Gaithersburg, MD). Approximately 5000 (in 50 µL) cells after the treatment 
were mixed with 250 µL of 1 % low melting point agarose in 1x PBS at 37 ºC. The 
mixture (75 µL) was quickly pipetted onto a Comet slide (Trevigen, Gaithersburg, MD) 
and allowed to solidify at 4 ºC. Slides were immersed for 30 min in prechilled lysis buffer 
(2.5 mM sodium chloride, 100 mM EDTA pH 10, 10 mM Tris Base, 1 % sodium lauryl 
sarcosinate, 0.01 % Triton X-100) at 4 ºC. After lysis, slides were incubated for 20 min in 
alkali solution (0.3 M NaOH, 1 mM EDTA) at room temperature to allow unwinding of 
DNA and then subjected to both neutral and alkaline electrophoresis for the next 20- 30 
min. Comet in an individual cell was stained with Comet silver staining kit (Trevigen, 
Gaithersburg, MD) and visualized using an online CCD camera. Fifty cells per treatment 
were analyzed using NIH ImageJ software to generate quantitative and statistical data. 
Cellular DNA damage was expressed as the “tail length” for neutral conditions and “tail 
moment” that combines a measurement of the length of the DNA migration and the 
relative DNA content therein, for the alkaline conditions (47).  
 
          6.2.9.     Measurement of apoptosis by Annexin V staining 
 Cells were continuously treated with fludarabine (0-20 μM), MX (3 mM) or both 
drugs in combination At 24 hrs after exposure to drugs, cells were harvested by 
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centrifugation. After two washes with PBS, cells were resuspended in 1 x binding buffer 
at a concentration of 1 x 106/mL.  Cells were exposed at room temperature for 15 min to 
5-μL Annexin V-FITC (BD Bioscience, San Jose, CA) following the instructions of the 
manufacturer. Analysis was carried out with FACSort (Becton Dickinson & Co., 
Mountain View, CA). 
 
6.2.10.  Cytofluorometric analysis of mitochondrial transmembrane potential 
(ΔΨm) by JC1 
 JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazoyl carbocyanine iodide, 
Cell Technologies, Mountain View, Ca) is a lipophilic cationic dye that enters the inner 
mitochondrial matrix in its monomeric form when the mitochondrial membrane is 
polarized (Reers et al., 1991, 1995). Cells were treated with the indicated amounts of 
drugs either alone or in combination for 24 hrs. Cells were then washed with 1 x  assay 
buffer and incubated for 15 min at 37  ºC with 1x JC1  reagent. In healthy cells the dye 
stains the mitochondria bright red. In the apoptotic cells, the mitochondrial membrane 
potential collapses and the JC1 reagent cannot accumulate within the mitochondria. In 
these cells JC1 remains in the cytoplasm in a green fluorescent monomeric form. The red 
form has absorption/emission maxima at 585/590 nm, while the green monomeric form 
has absorption/emission maxima at 510/527 nm. Cells were analyzed on FACSCalibur 
(Becton Dickinson, San Jose, CA) flow cytometer. 
 
     6.3.       Results 
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         6.3.1.     Higher BER activity and proteins expression are intrinsic properties  
       of CLL  
 Based on our previous studies showing that BER pathway is involved in response 
to fludarabine damage, we characterize the repair properties of CLL lymphocytes. The 
repair capacity of human CLL lymphocytes was evaluated in comparison with the 
activity of the normal lymphocytes or the activity of several types of human cancer cell 
lines. The enzymatic activity was determined by incubation of a specific BER substrate 
(synthetic 40 mer double-stranded oligonucleotide containing a deoxyuridine at the 
position 19) with cell extracts from these cells. Each sample was also subjected to 
western blot analysis and RT-PCR for protein expression and mRNA expression levels, 
respectively. As shown in Figure 6-1. A, the cell extracts from three different 
representative CLL samples had increased repair activity when compared with similar 
cell extracts from normal lymphocytes. The repair enzymatic activity was measured by 
incubation of the 40 mer double stranded oligonucleotide with 5 μg cell extracts for 30 
min at 37 ºC, which resulted in a cleaved fragment visualized by 19 % polyacrylamide 
denaturing gel. In contrast, when the enzymatic activity of CLL cell extracts was 
evaluated in comparison with extracts from other human cancer cell lines (Figure 6-1. A), 
similar levels were observed by in vitro enzymatic assays. Moreover, western blot 
analysis for endogenous expression levels of UDG and APE, enzymes responsible for 
enzymatic activity shown, were used to determine whether the increased enzymatic 
activity correlates to increased protein expression. Untreated CLL or normal cells were 
lysate and subjected for western blot analysis for UDG. The protein levels were 
quantitated based on densitometric analysis and normalized to the β-actin levels. As 
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shown in Figure 6-1. B, primary CLL cells exhibited a significant higher UDG 
expression levels compared with normal lymphocytes. An example of the blots used in 
these studies is also presented. Further analysis revealed that elevated UDG in CLL cells 
was accompanied by less dramatic elevation in APE levels when compared with normal 
cells (Figure 6-1. C). Additionally, we determined the basal expression levels of nuclear 
transcript of UNG by RT-PCR analysis. As Figure 6-1. D shows, the transcript levels in 
primary CLL samples were more heterogeneous, the majority of the samples expressed 
higher levels of UNG transcripts, while few had lower expression when compared with 
normal lymphocytes.  Among the population of normal cells, the expression of the 
transcripts was has uniform and low.  
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Figure 6-1 
Higher BER proteins expression levels and activity in CLL samples 
A, Cleavage of BER substrate (40 mer double-stranded oligonucleotide containing a 
deoxyuridine at the 19 position) by cell extracts from untreated CLL or normal donor 
lymphocytes. 5’-end labeled 40 mer oligonucleotides were incubated for 30 min, at 
37 ºC with 5 μg of several cell extracts. The products of reaction were analyzed by 
electrophoresis on 19 % denaturating polyacrylamide gels. Comparison of BER 
enzymatic activities of tumor cells, CLL and normal lymphocytes. The cleaved 
products were obtained after oligonucleotide substrates were incubated with 5 μg cell 
extracts. B, Same cell lysates were subjected to Western blot analysis with UDG and 
APE specific antibodies. Elevated levels of both UDG and APE enzymes in 
lymphocytes from CLL samples compared with lymphocytes from healthy donors. C, 
Quantification of UDG and APE basal protein expression levels in CLL samples 
versus normal samples. D, Quantification of UNG mRNA basal levels   in CLL 
versus ND samples, using RT-PCR analysis. Representative of three independent 
experiments. 
 
 
 186
 A   
 
 
 
 
40 mer
18 mer
ND CLL
Cell extract
UDG/APE
- +        + +       +        +       +      (5 µg)
+          - - - - - -
- +         + +        +         +      +      (5 µg)
+          - - - - - -
Cell extract
UDG/APE
SW480 HCT Jurkat  HL60   ND   CLL
40 mer
18 mer
 
B                                                                     C 
 
0
1
2
3
4
5
6
7
8
CLL ND
AP
E 
ex
pr
es
si
on
 
no
rm
al
iz
ed
 to
 B
-a
ct
in
APE
ND CLL
Actin
AP
E 
ex
pr
es
si
on
 
no
rm
al
iz
ed
 to
 B
-a
ct
in
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
CLL ND
UD
G
 e
xp
re
ss
io
n 
no
rm
al
iz
ed
 to
 B
-a
ct
in
UDG
Actin
ND CLL
UD
G
 e
xp
re
ss
io
n 
no
rm
al
iz
ed
 to
 B
-a
ct
in
 
 
D  
 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5
CLL ND
U
N
G
 m
R
NA
 e
xp
re
ss
io
n 
no
rm
al
iz
ed
 to
 B
-a
ct
in
 
 
 
 
 
 187
    6.3.2.     In fludarabine treatment of CLL lymphocytes, ara-AP sites are  
  formed following BER activation and are bound by MX. 
 The promising observed difference in repair activity between CLL and normal 
lymphocytes led us to evaluate BER response in processing fludarabine residues by 
measuring the formation of arabinosyl (ara)-AP sites in CLL lymphocytes after drug 
treatments. We measured the ara-AP sites formed in cells using AP site assay based on 
the capacity of the aldehyde reactive probe reagent (ARP) to bind to the aldehyde free 
moiety of the AP site. Human lymphocytes were incubated with fludarabine in the 
presence or absence of MX. Total genomic DNA was isolated, labeled with ARP and 
analyzed. As shown in Figure 6-2. A, the number of ara-AP sites in DNA proportionally 
increased with the concentration and with the duration of exposure to fludarabine (Figure 
6-2. B). Co-treatment with MX reduced detectable ara-AP sites generated by fludarabine. 
This reduction of ara-AP sites is presumably due to the binding of MX to the aldehyde 
group of the ara-AP site to form a MX-bound AP-sites (31, 36), thereby making the ara-
AP sites unavailable for ARP. These results demonstrate that lymphocyte exposure to 
fludarabine initiates BER response.  
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Figure 6-2 
Fludarabine induces ara-AP sites formation due to the presence of active BER 
pathway in CLL lymphocytes 
A, The dose-dependent relationship between the numbers of ara-AP sites and the 
concentrations of fludarabine. CLL lymphocytes were treated with fludarabine alone (0-
20 μM) or fludarabine plus MX (3 mM) for 24 hrs. Genomic DNA was extracted and 
ara-AP sites were measured using aldehyde reactive probe reagent (*, p<0.05). B, The 
time-dependent relationship between the number of ara-AP sites and the time of 
exposure to fludarabine. CLL lymphocytes were treated with fludarabine alone (5 μM) or 
fludarabine plus MX (3 mM). Cells were collected at 24, 48 and 72 hrs treatments and 
ara-AP sites were measured using ARP. Data represents the mean of at least triplicate 
experiments.  
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           6.3.3.      BER proteins UDG and pol β are upregulated in CLL cells co-treated 
                          with fludarabine and MX 
 To further characterize the involvement of BER in the process of DNA damage 
induced by fludarabine or by the combination of fludarabine with MX, we subsequently 
evaluated the expression of BER proteins: UDG, APE, FEN1, pol β and PCNA in 
lymphocytes before and after drug treatment. UDG and pol β were up-regulated after 
exposure to either fludarabine alone or the combination. Still, a more significant elevation 
of these two proteins was observed in cells treated with fludarabine plus MX (Figure 6-3. 
A) and their up-regulation persisted over a period of 72 hrs. In contrast, APE levels did 
not change before and after drug treatment indicating that MX and MX-bond AP sites 
have no direct effect on APE. To investigate whether the induction of UDG protein levels 
is regulated at the transcriptional levels, a real time RT-PCR assay was used. CLL 
lymphocytes were treated with fludarabine alone (10 μM) or fludarabine plus MX ( 3 
mM) for 24 hr. The RNA was isolated, cDNA was prepared and analyzed using TagMan 
MGB probes and RT-PCR amplification. The values obtained for the target gene were 
normalized to β-actin values (endogenous control) for each sample. Results presented in 
Figure 6-4 showed that at 24 hr, the UNG transcript levels were 2-3 folds increased after 
exposure of cells to combined treatments, when compared to fludarabine alone. The 
mechanism of BER proteins induction remains to be further elucidated; these results 
indicate that the BER pathway is targeted and activated as an adaptive response to the 
DNA damage formed by fludarabine and the combination in human CLL lymphocytes. 
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Figure 6-3 
Induction of protein and mRNA expression of BER related enzymes  
as a response to fludarabine and MX combined treatment 
CLL lymphocytes were continuously treated with fludarabine alone (5 µM) or 
fludarabine plus MX (3 mM) and collected at 24, 48 and 72 hrs. Cell lysates were 
subjected to Western blot analysis with UDG, polymerase β, APE1, Fen1, PCNA and 
tubulin specific antibodies. C = control, F = Fludarabine alone, F + M = Fludarabine plus 
MX; M = MX.   
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Figure 6-4.  
Induction of mRNA levels of nuclear isoform of UNG 
A, CLL lymphocytes were continuously treated with fludarabine alone (10 µM) or 
fludarabine plus MX (3 mM) and collected at 24 hr. The RNA was isolated; cDNA was 
prepared and analyzed using TagMan MGB probes and RT-PCR amplification. The 
values obtained for the target gene were normalized to β-actin values (endogenous 
control) for each sample. UDG transcript level for each individual patient is presented. B, 
Average values. 
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         6.3.4.     MX combined with fludarabine generates DNA strands breaks  
 We have shown previously that the combination of MX and fludarabine or 
alkylating agents such as BCNU or TMZ, increased DNA strand breaks in cancer cell 
lines, leading to cell death (31, 42-44). We used comet assay to asses the induction of 
DNA strand breaks by fludarabine or the combination with MX in CLL lymphocytes. 
DNA damage in a single cell was assayed by neutral electrophoresis to detect double 
strand breaks and representative Comet images are shown in Figure 6-5. A. When 
quiescent human lymphocytes were incubated for 24 hrs in the presence of various 
concentrations of fludarabine plus 3 mM MX, a dose dependent increase in the tail length 
was observed. In contrast, fludarabine alone at the same concentrations range (0-20 μM) 
had no significant effect on comet formation and tail length. The levels of strand breaks 
were evaluated by assessing tail lengths of at least 50 comets for each experimental 
regimen. Results showed that MX enhanced 2-4 folds the tail length when combined with 
fludarabine (Figure 6-5. B). In addition, time course treatments in the same experimental 
conditions were used to determine the persistence or the repair of strand breaks after 
either single agent (5 μM fludarabine, 3 mM MX) or combined treatments. As illustrated 
in Figure 6-5. C, the DNA damage induced by 5 μM fludarabine was minimal over a 72 
hrs period. However, when cells were treated with fludarabine combined with MX, the 
comet tail length was significantly increased and it failed to recover (to control values) 
over 72 hr which suggests that MX suppressed any repair process of the fludarabine-
induced DNA damage. 
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Figure 6-5 
MX enhances fludarabine-induced DNA single and double strand breaks in CLL 
A, Comet images, neutral conditions. CLL lymphocytes were treated continuously with 
5-20 µM fludarabine and /or fludarabine plus 3 mM MX for 24 hrs. B, Tail length of the 
comet formed in neutral electrophoresis after dose-dependent treatments with fludarabine 
alone (0-20 μM) and fludarabine plus MX (3 mM) C, Tail length of comet formed after 
continuously treatments with 5 µM fludarabine or fludarabine plus 3 mM MX for 24, 48 
and 72 hrs. Data represent the mean of at least triplicate experiments, * p<0.05.  
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        6.3.5.    Induction of Topoisomerase IIα levels correlates with CLL sensitivity     
 to the combined treatments 
 One mechanism involved in the generation of double-strand breaks relies on the 
formation of MX-bound ara-AP sites refractory to BER that can act as topoisomerase 
poisons to stabilize the DNA-topoisomerase IIα cleavable complex. Thus, the 
endogenous and drug-related topoisomerase IIα (topo II) levels were measured. We 
compared the basal levels of protein expression and transcript in fresh CLL cells with that 
of normal lymphocytes obtained from healthy donors. As shown in Figure 6-6 A, the 
protein expression in all CLL lymphocytes was higher compared with normal cells. 
Moreover, analysis of the topo II transcript levels by RT-PCR revealed that higher 
protein expression is due to higher transcript levels, when compared with normal cells 
(Figure 6-6. B). These results are in agreement with our previously published data that 
there is a difference of 20 fold in topo II expression between primary cells and tumor cell 
lines. Next, the drug-related induction of topo II at the levels of protein expression and 
transcript were measured by Western Blot and RT-PCR analysis, respectively. As shown 
in Figure 6-6. C,  prolong induction of topo II was seen in CLL lymphocytes over a 
period of 72 hr after exposure of cells with fludarabine plus MX, compared with 
treatment with fludarabine alone. We then examined the relationship between induced 
protein expression and the transcript levels in lymphocyte cells before and after drug 
treatments. The total RNA was extracted from CLL lymphocytes treated with either 
fludarabine alone or in combination with MX and topo II transcript levels were assayed 
by RT-PCR analysis. Results showed a 2-3 fold increase in topo II transcript levels after 
fludarabine plus MX treatments (Figure 6-7) in each sample tested. 
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To correlate the DNA strand breaks accompanied by induction of topo II with the killing 
effect determined by the drug treatments, cell death was assayed. Lymphocytes from 
CLL were treated with 5 µM fludarabine or fludarabine plus 3 mM MX and cells were 
counted every day using triptan blue exclusion. As shown in Figure 6-6. D, lymphocyte 
cells were sensitive to the combination of fludarabine and MX, MX enhancing 
fludarabine cytotoxicity by 2 fold. 
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Figure 6-6 
MX enhances fludarabine induced cell death in CLL due to induction of 
Topoisomerase IIα levels 
A, Comparison of the mRNA levels of topoisomerase IIα between human CLL 
lymphocytes and human normal lymphocytes, assayed by RT-PCR. B, CLL lymphocytes 
were continuously treated with fludarabine alone (5 µM) or fludarabine plus MX (3 mM) 
and collected at 24, 48 and 72 hrs. Cell lysates were subjected to Western blot analysis 
with topoisomerase IIα and tubulin specific antibodies. C = control, F = Fludarabine 
alone, F + M = Fludarabine plus MX; M = MX. C, Comparison of the levels of 
topoisomerase IIα between human CLL lymphocytes and human normal lymphocytes, 
assayed by western bloting. Representative of three independent experiments. D, The CLL 
lymphocytes were treated with fludarabine (5 µM) and fludarabine plus MX (3 mM). Cell 
viability was determined by tryptan blue exclusion. Cell viability is expressed as 
percentage of untreated control. (* p<0.05). 
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Figure 6-7.  The Topo II mRNA expression after treatments. 
A, CLL lymphocytes were continuously treated with fludarabine alone (10 µM) or 
fludarabine plus MX (3 mM) and collected at 24 hr. The RNA was isolated, cDNA was 
prepared and analyzed using TagMan MGB probes and RT-PCR amplification. The 
values obtained for the target gene were normalized to β-actin values (endogenous 
control) for each sample. Topo IIα transcript level for each individual patient is 
presented. B, Average values. 
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6.3.6.     MX blocks the repair of Fludarabine-induced mitochondrial DNA        
damage and leads to mitochondrial mediated apoptosis  
 Since mitochondrial DNA (mtDNA) is potentially targeted by fludarabine, the 
effects of fludarabine alone and the combination with MX were determined at the levels 
of mtDNA. CLL lymphocytes were exposed to increased fludarabine concentrations, 
ranging from 0 to 20 μM for 24 hrs. MtDNA was extracted and mtAP-sites were 
quantitated using ARP reagent. As shown in Figure 6-8. A, increased drug concentrations 
resulted in proportionally higher levels of mtAP-sites (r = 0.971). This suggests that 
fludarabine targets mtDNA and that the induced damage is processed by the 
mitochondrial repair pathway. However, when cells were treated with fludarabine and 
methoxyamine (3 mM) detectable AP sites were reduced almost to the control levels due 
to binding of MX. This suggests that MX is able to bind not only nuclear, but also 
mitochondrial AP sites. The large extent of persistent fludarabine-induced nuclear and 
mitochondrial DNA damage due to MX suggests that MX-AP sites are key DNA lesions 
which potentiate the apoptotic death of fludarabine. Thus, apoptosis was assayed. 
Exposure of cells to fludarabine alone (0- 20 μM) for 24 hrs resulted in a modest degree 
of apoptosis (6 % increase over control values at 20 μM). However, combination of 
fludarabine with MX for 24 hrs resulted in a 2-fold increase in apoptosis (14 % at 20 μM) 
(Figure 6-8. B). Similar potentiation of apoptosis by MX was seen in a time course 
analysis (data not shown). To further determine the role of mitochondria in apoptosis 
mechanism, we measured treatment-mediated changes in mitochondrial membrane ΔΨm 
using fluorescent mitochondrial probe JC-1. Time course response analysis of CLL 
lymphocytes treated with 5 μM fludarabine revealed that the percentage of cells which 
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lost their mitochondrial membrane integrity and, subsequently, their ability to accumulate 
JC1 dye increased from 7 % at 24 hrs to 30 % at 72 hrs (Figure 6-8. C). When cells were 
co-treated with MX the percentage of cells with damaged mitochondria increased to 29 % 
at 24 hrs and to 42 % at 72 hrs, respectively. Moreover, the results were confirmed by 
western blot analysis for mitochondrial related apoptotic proteins. As shown in Figure 6-
6. D, combined treatment resulted in a very clear induction of pro-apoptotic protein Bax 
at 24 hrs and lasted for at least 72 hrs. Since a key marker of mitochondrial apoptotic 
cascade is the activation of caspase 9 by proteolytic cleavage, we examined the levels of 
the cleaved fragment (Figure 6-8. D). Cleaved caspase 9 was observed at 48 hrs and 72 
hrs after treatment with fludarabine alone or fludarabine plus MX. However, in 
fludarabine plus MX treatments caspase 9 cleavage was ~2-fold greater than in cells 
treated with fludarabine alone. Similar results were obtained for another marker of the 
apoptotic cascade, the proteolytic cleavage of PARP by caspases (Figure 6-6. D). No 
changes were observed in the expression levels of Bcl2, an anti-apoptotic molecule. 
Together, these results demonstrate that MX potentiates fludarabine in vitro. Results also 
demonstrate that fludarabine induced ara-AP sites in mitochondrial DNA and they 
suggest that the mtDNA damage could play a significant role in mediating activation of 
apoptosis and cell death following fludarabine treatments. 
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Figure 6-8 
Mitochondrial DNA damage and activation of mitochondrial-mediated cell death 
A, The dose–dependent relationship between the numbers of mitochondrial ara-AP sites 
and the concentrations of fludarabine. CLL cells were continuously treated with 
fludarabine alone (0-20 µM) or fludarabine plus MX (3 mM). Mitochondrial DNA was 
extracted and ara-AP sites were measured using aldehyde reactive probe reagent. (*, 
p<0.05). B, Induction of apoptosis by the combined treatment fludarabine and 
methoxyamine. CLL lymphocytes were continuously treated with fludarabine alone (5 
μM) or fludarabine plus MX (3 mM), collected at 24 hrs and assayed for apoptosis by 
Annexin V staining and flow cytometry analysis. C, Increased mitochondrial membrane 
potential loss measured in cells treated with combined agents for 24 hrs. D, Aliquots of 
the samples used in B were subjected to Western blot analysis with Bcl2, Bax, Cleaved 
caspases 9, Cleaved PARP and tubulin specific antibodies. Control (lane 1), fludarabine 
alone (lane 2,4,6) and fludarabine plus MX lanes (3,5.7), MX alone (lane 8). 
Representative of three independent experiments. 
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6.4.      Discussion 
 Base excision repair is a major repair pathway that corrects DNA modifications 
arising either spontaneously or after attack by exogenous DNA damaging factors, such as 
certain cancer therapies. An efficient BER can reverse the DNA damage caused by 
therapeutic agents leading to development of resistance. However, BER therapeutic 
implications have been evaluated by several targeted approaches, such as blocking of the 
repair pathway by methoxyamine (MX) or PARP-inhibitors (48). In this study we 
underlined the possibility of exploiting BER pathway in primary CLL lymphocytes as a 
basis for targeted combinatory therapy involving standard therapeutic agent, fludarabine. 
This conclusion is based on several lines of evidence. (i) The primary lymphocytes 
isolated from CLL patients exhibited higher BER proteins expressions and increased BER 
activity when compared to normal lymphocytes. (ii) BER involvement in response to 
fludarabine-induced damage was confirmed by generation of ara-AP sites. (iii) Ara-AP 
sites formed by fludarabine were bound by MX leading to induction of protein levels of 
key BER proteins and resulted in DNA strand beaks and cell death. (iv) Mitochondrial 
DNA was found to be a target of fludarabine and MX that triggers mitochondrial mediated 
apoptosis following disruption of mitochondrial BER.  
Fludarabine-induced cytotoxicity is enhanced when active BER pathway in primary 
CLL is inhibited by MX.  
BER is more active in CLL compared with normal lymphocytes. BER is an important 
factor in cancer treatment based on several considerations: drug efficacy is influenced by 
the efficiency of repair pathway, increased levels of DNA repair proteins have been 
correlated with resistance to anticancer agents acting as DNA-damaging agents and 
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understanding the repair pathway have made it potentially ‘druggable’ target for the 
enhanced anti-tumor activity of DNA-damaging agents (48). Based on our previous 
studies (Chapter 3, Chapter 4), two BER proteins have been shown to play an important 
role in response to fludarabine induced damage: UDG and APE. When comparing the 
basal levels of these proteins along with their activity on specific BER substrates, the 
results showed a clear, significant difference: both proteins have higher expression levels 
and activity in CLL cells, compared with normal lymphocytes. In contrast, the protein 
expression pattern in CLL samples is similar with the ones measured in other human 
cancer cells. Although more studies are needed, these findings suggest a possible 
mechanism of resistance of CLL lymphocytes toward fludarabine and set the stage for 
potential combinatory therapy to reduce the development of resistance to fludarabine.  
Additionally, based on this difference between the normal and tumor primary cells, 
targeting BER may be a selective approach to enhance fludarabine potency with lower 
toxicity toward normal tissue. Furthermore, the intrinsic higher level of expression of 
BER proteins may play a role in the limited sensitivity of CLL for fludarabine.  
MX stabilizes ara-AP sites induced by fludarabine. Intermediates in BER, AP-sites are 
formed as a consequence of the removal of modified bases by DNA glycosylases, the 
first step in BER pathway. We have previously identified (Chapter 3 and Chapter 4) that 
uracil DNA glycosylase plays a role in processing of incorporated fludarabine leading to 
formation of ara-AP sites (21). In the present study, we report that fludarabine treatment 
of lymphocytes from CLL samples resulted in a dose- and time- dependent formation of 
ara-AP sites, suggesting that the repair pathway is involved in response of lymphocytes to 
fludarabine-induced DNA damage. Also, our results confirmed that non-toxic doses of 
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MX are sufficient for effective binding of the ara-AP sites formed by fludarabine. BER 
involvement in response to MX plus fludarabine treatments of CLL was also confirmed 
by increased expression levels of UDG and polymerase β.  
MX-bound AP-sites generate double strand breaks and cell death. Formation of MX-
bound AP-sites following treatment with fludarabine and MX resulted in double strand 
breaks and cell death.  This increase in double stranded breaks can be explained by 
previous data from our laboratory demonstrating that AP sites can act as topoisomerase II 
poisons, trapping the protein into stabilized cleavable complexes (31). Indeed, formation 
of MX-bound AP-sites was accompanied by higher expression levels of topo II in CLL 
cells supporting the above mentioned scenario.  
Fludarabine and MX treatment triggers mitochondrial mediated apoptotic cell 
death in CLL cells.  To determine the mechanism of apoptotic cell death, we focused on 
mitochondrial involvement in this process. MtDNA is more prone to cytotoxic damage 
due to several factors such as lack of protective histone, production of reactive oxygen 
species and limited repair capacities (41,43). Recent studies showed that BER pathway is 
the predominant repair pathway in mitochondria (42). Thus, we measured the formation 
of ara-AP sites in mtDNA after exposure to fludarabine. Data have shown that 
mitochondrial ara-AP sites formation is in dose dependent fashion and that MX binds 
these ara-AP sites, thereby blocking the BER pathway in mitochondria. The level of 
mtDNA damage eventually becomes severe, mitochondria lose their ability to maintain 
the membrane potential and activate mitochondrial apoptotic death pathway.  
 These results suggest a possible synergistic approach for enhancing fludarabine 
cancer therapy that involves disruption of base excision repair in CLL lymphocytes. This 
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therapeutic strategy could improve both therapeutic index by decreasing the dose of 
anticancer drugs and therapeutic efficacy for the treatment of hematological 
malignancies.  
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CHAPTER VII   
SUMMARY AND FUTURE DIRECTIONS 
 
 
 
The work presented here focused on investigating the involvement of BER 
pathway in the response to fludarabine induced DNA damage and the possibility of 
enhancing antineoplastic activity of fludarabine by inhibition of BER (e.g. 
methoxyamine).  Key findings of this research include: 
(i) Uracil DNA glycosylase is the BER enzyme responsible for recognition and removal 
of fludarabine incorporated into DNA strand, triggering activation of BER pathway 
and subsequent formation of ara-AP sites. 
(ii) By completion of BER, the cytotoxic potential of fludarabine is diminished, 
suggesting a possible mechanism of resistance. 
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(iii) MX, an inhibitor of BER, enhances fludarabine cytotoxicity through its ability to bind 
to fludarabine-induced ara-AP sites; new MX-bound AP-sites formed are resistant to 
BER action and the blockage of BER increases cell death in vitro and in human 
xenografts. 
(iv) Mitochondrial DNA is a target of fludarabine plus MX; inhibition of mtBER leads to 
accumulation of mtDNA damage that will eventually result in mitochondrial 
mediated apoptotic cell death. 
(v) MX potentiates the antineoplastic activity of fludarabine in primary CLL 
lymphocytes, setting the stage for the development a novel therapeutic strategy by 
combining the inhibitor of BER (MX) with fludarabine.  
 
 The chart in next page outlines the connection between the main results presented 
in this thesis, results which also set up the basis for future investigations.  
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Figure 7-1. Conclusions 
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Future efforts will be directed toward three main focus areas: 
(i) Uracil DNA glycosylase and other BER glycosylases.  
 Investigations involving crystal structure of human UDG bound to DNA 
containing F-ara-A should help elucidating the mechanism by which UDG recognizes 
and removes fludarabine base from DNA helix and establishing the specific role of the 
fluorine substitute in the biochemical mechanism of the enzymatic reaction.  
 Studies aimed to understand “if and how” the localization of incorporated 
fludarabine (in-DNA-strand vs. at-3’-DNA-end) is important for UDG activity will be 
carried out, starting with oligonucleotide substrates containing fludarabine at different 
positions and in vitro tests.  
(ii) Mitochondrial involvement in the apoptotic cell death.  
 Detection of early apoptotic events is of crucial importance. To understand more 
precisely the sequential steps in fludarabine-induced apoptosis, we will continue the 
studies presented in Chapter 5, where we have shown that not only nuclear DNA, but also 
mtDNA is a target for fludarabine. Next question: Is the mitochondrial DNA damage 
prevailing in signaling for apoptosis?  
iii) Translating the preclinical data into clinical use. 
As underlined in Chapter 6, preliminary studies using primary CLL cells have 
shown promising results regarding the therapeutic potential of the combination 
fludarabine plus MX. Thus, we will aim to include this combination into clinical 
application. While the path toward implementing a new therapy is a very long and 
complex endeavor, small but well coordinated steps and perseverance are some of the 
necessary ingredients for success.  
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